SOLID DISPERSIONS CONTAINING 20-O-beta-D-GLUCOPYRANOSYL-20(S)-PROTOPANAXADIOL

The present invention provides solid dispersion, comprising: 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol which is a pharmacologically active ingredient; and a saturated polyglycolized glyceride which is a lipid matrix. The solid dispersion of the present invention has effects of increasing dissolution rate of 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol.

USE OF LEUKOTRIENE B4 IN COMBINATION WITH A TOLL-LIKE RECEPTOR LIGAND, A RIG-I-LIKE RECEPTOR LIGAND, OR A NOD-LIKE RECEPTOR LIGAND TO ENHANCE THE INNATE IMMUNE RESPONSE

The present invention relates to the use of leukotriene Bto enhance the response of Toll-like receptor (TLR), RIG-I-like receptor (RLR), and NOD-like receptor (NLR) when stimulated simultaneously with respective proper ligands. The use in combination of LTBwith those ligands is useful to potentiate immune response for the treatment of autoimmune diseases, immunosuppressive diseases, as well as immunological disorders. 174-. (canceled)75. A pharmaceutical composition comprising leukotriene B(LTB) and at least one modulator of a receptor selected from the group consisting of a Toll-like receptor (TLR) , a RIG-I-like receptor (RLR) , and a NOD-like receptor (NLR) , for potentiating an immune response , for stimulating neutrophils , for stimulating secretion of a pro-inflammatory cytokine , for stimulating intracellular kinase activation , for stimulating release of Tumor necrosis factor α (TNF-α) or for treating a viral infection.7690-. (canceled)91. The pharmaceutical composition of claim 75 , wherein said kinase is TAK-1 claim 75 , p38 claim 75 , a c-Jun N-terminal kinase (JNK kinase) or a combination thereof.9299-. (canceled)100. The pharmaceutical composition of claim 75 , wherein said viral infection is from cytomegalovirus.101. The pharmaceutical composition according to claim 75 , wherein said Toll-like receptor is selected from the group consisting of TLR1 to TLR10.102. The pharmaceutical composition according to claim 75 , Toll-like receptor is a TLR1/2 complex.103. The pharmaceutical composition according to claim 75 , wherein said Toll-like receptor is a TLR2/6 complex.104. The pharmaceutical composition according to claim 75 , wherein said Toll-like receptor is a TLR1 claim 75 , TLR2 claim 75 , TLR4 claim 75 , TLR5 or TLR6.105. The pharmaceutical composition according to claim 75 , wherein said Toll-like receptor is a TLR3.106. The pharmaceutical composition according to claim 75 , wherein the modulator of said Toll-like receptor is a TLR2 ligand claim 75 , ...

LIVER FUNCTION-IMPROVING AGENT

The present invention provides a liver function-improving agent or an inhibitor of fat accumulation in the liver, which contains maltitol as an active ingredient. The present invention also provides a medicament for the prevention and/or treatment of hepatic dysfunction, which contains maltitol as an active ingredient. 1. A method of preventing and/or treating hepatic dysfunction , which comprises administering an effective amount of maltitol to a subject in need of the prevention and/or treatment of hepatic dysfunction.2. The method according to claim 1 , wherein the prevention and/or treatment of hepatic dysfunction is achieved through inhibition of fat accumulation in the liver claim 1 , inhibition of hepatic fibrosis claim 1 , and/or inhibition of hepatic inflammation.3. The method according to claim 1 , wherein the hepatic dysfunction is due to a hepatic disease selected from the group consisting of alcoholic fatty liver claim 1 , non-alcoholic fatty liver claim 1 , alcoholic steatohepatitis claim 1 , non-alcoholic steatohepatitis claim 1 , liver cirrhosis and liver cancer.4. The method according to claim 1 , wherein the maltitol is administered as a sole active ingredient.5. The method according to claim 1 , wherein the maltitol is administered in the form of solution.6. The method according to claim 1 , wherein the maltitol is administered in the form of food or drink to which the maltitol has been added.7. A method of improving liver function in a subject claim 1 , which comprises administering an effective amount of maltitol to the subject whose liver function is decreased relative to a normal state.8. The method according to claim 7 , wherein the improvement of liver function is characterized by an improvement in blood AST value and/or blood ALT value of a subject.9. The method according to claim 7 , wherein the maltitol is administered as a sole active ingredient.10. The method according to claim 7 , wherein the maltitol is in the form of solution.11. The ...

METHODS AND COMPOSITIONS FOR TREATMENT OF METABOLIC DISORDERS

The present invention relates to the discovery that increases in invariant NKT cell (iNKT) number and/or activity can reduce the incidence or severity of metabolic disorders such as obesity and diabetes. The invention accordingly features methods, kits, and compositions for the treatment of such metabolic disorders by administration of a composition capable of increasing iNKT activity. 1. A method of treating a subject suffering from a metabolic disorder , said method comprising administering to said subject a sufficient amount of a composition that increases invariant NKT (iNKT) cell activity.2. The method of claim 1 , wherein said composition comprises a glycolipid; an antibody or an antigen-binding fragment thereof; or an iNKT.3. The method of claim 2 , wherein said glycolipid is a bacterial glycolipid capable of activating iNKT.4. The method of claim 2 , wherein said glycolipid is α-galactosylceramide or an analog thereof.5. The method of claim 2 , wherein said antibody or antigen-binding fragment thereof specifically binds to an iNKT and increases activity of said iNKT.6. The method of claim 5 , wherein said antibody or antigen-binding fragment thereof binds to the CDR3 loop or the α-β junction of said iNKT.7. The method of claim 2 , wherein said iNKT is an autologous iNKT.8. The method of claim 1 , wherein said composition further comprises a pharmaceutically acceptable carrier.9. The method of claim 8 , wherein said composition is administered intravenously claim 8 , intramuscularly claim 8 , orally claim 8 , by inhalation claim 8 , parenterally claim 8 , intraperitoneally claim 8 , intraarterially claim 8 , transdermally claim 8 , sublingually claim 8 , nasally claim 8 , transbuccally claim 8 , liposomally claim 8 , adiposally claim 8 , ophthalmically claim 8 , intraocularly claim 8 , subcutaneously claim 8 , intrathecally claim 8 , topically claim 8 , or locally.10. A method for treating a subject suffering from a metabolic disorder claim 8 , said method ...

ADJUVANT COMBINATIONS COMPRISING AN NKT ACTIVATOR, A CD40 AGENT, CD40 AGONIST, AND OPTIONAL ANTIGEN, THE USE THROUGH INDUCING SYNERGISTIC CELLULAR IMMUNITY

Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (α-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is also provided. 1. An adjuvant combination which elicits a synergistic effect on T cell immunity comprising:(i) at least one agonist of CD40;(ii) at least one NKT activator; and(iii) optionally at least one desired antigen.233-. (canceled)34. A method of promoting immunity to an infectious agent in a subject in need thereof , consisting of the administration of a combination of adjuvants consisting of: (i) a human CD40 agonist , which is selected from an agonistic CD40 antibody or an agonistic CD40 antibody fragment or a multimeric CD40L polypeptide or multimeric CD40L protein fragment; (ii) alpha-galactosyl ceramide , and (iii) optionally an infectious agent antigen , wherein the administration of said combination elicits a synergistic enhancement of CD70 expression on an immune cell relative to either the CD40 agonist or the alpha galactosyl ceramide administered as a monotherapy.35. method of claim 34 , wherein the infectious agent is selected from a virus claim 34 , bacterium claim 34 , fungus and parasite.36. The method of wherein said infectious agent is a virus and the method includes the administration of a viral antigen from a virus selected from the group consisting of HIV claim 35 , herpes claim 35 , papillomavirus claim 35 , ebola claim 35 , picorna claim 35 , enterovirus claim 35 , measles virus claim 35 , mumps virus claim 35 , bird flu virus claim 35 , rabies virus claim 35 , VSV claim 35 , dengue virus claim 35 , hepatitis virus claim 35 , rhinovirus claim 35 , yellow fever virus claim 35 , bunga virus claim 35 , polyoma virus claim 35 , coronavirus claim 35 , rubella virus claim 35 , echovirus claim 35 , pox virus claim 35 , varicella zoster claim 35 , African swine fever virus claim 35 , ...

Rhizoma Arisaematis Extracts and Uses Thereof for Wound-Healing Effects

Provided are water and alcohol extracts of , compounds isolated from (such as 3-O-(9,12-octadecadienoyl)-glyceryl-β-D-galactopyranoside, N-(β-D-ribofuranos-1-yl)-phenylalanine, and adenosine), pharmaceutical compositions comprising the aforementioned ingredients, as well as uses thereof for promoting wound healing. In one embodiment, the pharmaceutical composition is a topical formulation, such as a cream, ointment, foam, lotion, plaster, gel, and emulsion. 1Rhizoma arisaematis. A method for promoting healing of a wound in a subject , comprising administering to the subject , a therapeutically effective amount of a composition comprising a water-soluble extract , and/or one or more isolated compounds selected from the group consisting of 3-O-(9 ,12-octadecadienoyl)-glyceryl-β-D-galactopyranoside , N-(β-D-ribofuranos-1-yl)-phenylalanine , adenosine , and any salts thereof.2Rhizoma arisaematis.. The method according to claim 1 , wherein the composition comprises a water soluble extract of the root of3. The method according to claim 1 , wherein the composition comprises one or more isolated compounds selected from the group consisting of 3-O-(9 claim 1 ,12-octadecadienoyl)-glyceryl-β-D-galactopyranoside claim 1 , N-(β-D-ribofuranos-1-yl)-phenylalanine claim 1 , adenosine claim 1 , and any salts thereof.4. The method according to claim 3 , wherein the composition comprises an isolated compound that is 3-O-(9 claim 3 ,12-octadecadienoyl)-glyceryl-β-D-galactopyranoside or a salt thereof claim 3 , and an isolated compound that is adenosine or a salt thereof.5. The method according to claim 1 , wherein the composition is topically administered to a wound area.6. The method according to claim 1 , wherein the subject has a skin wound claim 1 , excision claim 1 , laceration claim 1 , burn claim 1 , abrasion claim 1 , penetrating wound claim 1 , surgical wound claim 1 , crushing injury claim 1 , or ulcer.7. The method according to claim 6 , wherein the subject has a diabetic ...

COMPOSITION FOR BUFFERED AMINOALKYL GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND ITS USE FOR ENHANCING AN IMMUNE RESPONSE

There is provided a composition comprising an aminoalkyl glucosaminide phosphate compound or a pharmaceutically salt thereof and a buffer for use as an immunomodulator. 1. A composition comprising (i) an aminoalkyl glucosaminide phosphate or a pharmaceutically acceptable salt thereof and (ii) an effective amount of a HEPES buffer sufficient to provide a pharmaceutically acceptable pH range.2. The composition of wherein said buffer is selected from the group consisting of HEPES having a pH that is within a pharmaceutically acceptable pH range.3. The composition according to wherein said buffer is HEPES having a pH between about 7 and about 8.4. The composition according to having a pH of about 7.0.5. The composition according to having a pH=7.0.7. The composition of wherein n is an integer from 0 to 2 inclusive.8. The composition of wherein R claim 6 , R claim 6 , and Reach independently contain from about 7 to about 16 carbon atoms.9. The composition of wherein R claim 6 , R claim 6 , and Reach independently contain from about 9 to about 14 carbon atoms.10. The composition of wherein n is 0.11. The composition of wherein Ris CO2H.12. The composition of wherein Ris POH.13. The composition of wherein Ris H.17. The composition of wherein Ris a phosphate group and the counterion is selected from the group consisting of monoethanolamine claim 6 , diethanolamine and triethanolamine.18. The composition of wherein the counterion is the monoethanolamine.19. The composition of wherein the counterion is the monoethanolamine.20. The composition of in the form of a dispersion.21. The composition of in the form of a solution.22. The composition of or in the form of a clear solution.23. The composition of in which the mixture claim 22 , solution claim 22 , and clear solution is nanoparticulate composition having a particle size of ≦200 mμ.24. The composition of wherein said solution is used as an immunomodulator.25. The composition of wherein said composition has a sterile ...

METHOD FOR TREATMENT OF DISEASE WITH PURE PORCINE MONOSIALOGANGLIOSIDE GM1

A process for preparing pure monosialoganglioside GM1 in the form of its sodium salt. There is provided a process for the isolation and purification of monosialoganglioside GM1 comprising (a) separation of GM1 from a lipidic mixture containing the monosialoganglioside GM1 as the main ganglioside component by ion exchange column-chromatography using an eluent comprising potassium or caesium ions, (b) recovery of the solute from the eluted solution, (c) diafiltration of an aqueous solution of the recovered solute, and (d) second diafiltration after the addition of 1 M NaCl, and recovering GM1. The purity level of GM1 obtained is higher than 99.0%. 115-. (canceled)16. A method of treating disorders and diseases of the central and peripheral nervous systems , comprising administering to a patient in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a porcine monosialoganglioside GM1 produced according to a process for the purification of monosialoganglioside GM1 comprising separating monosialoganglioside GM1 from Fucosyl-GM1 in a lipidic mixture containing the monosialoganglioside GM1 as the main ganglioside component , by ion exchange column-chromatography using an eluent comprising potassium or caesium ions , wherein said porcine monosialoganglioside GM1 comprises less than 0.1% Fuc-GM1.17. The method according to wherein the disorder or disease of the central or peripheral nervous system is selected from the group consisting of cerebral stroke claim 16 , Parkinson's disease claim 16 , spinal cord injury claim 16 , Alzheimer's disease claim 16 , Tardive Dyskenisia claim 16 , Amyotrophic Lateral Schlerosis claim 16 , peripheral neuropathies and autonomic neuropathy.18. The method of wherein said composition further comprises a pharmaceutically acceptable carrier.19. The method according to claim 16 , wherein said porcine monosialoganglioside GM1 is at least 99.0% pure.20. The method according to claim 19 , wherein the disorder ...

METHOD FOR TREATING HIV

The present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, Crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones. Treatment can be carried by introduction of the intermediary metabolite into the afflicted subject or by a reagent that when administered leads to elevated levels. The treatment regimen can be in vivo or ex vivo. 1. A method for treating HIV in a human subject , comprising:administering to a human subject in need of treatment for HIV an effective amount of β-galactosylceramide.2. The method of claim 1 , wherein said administration is selected from the group consisting of intravenous administration claim 1 , intra-muscular administration claim 1 , subcutaneous administration claim 1 , intra-peritoneal administration and oral administration.32. The method of claim claim 1 , claim 1 , wherein said administration comprises intravenous administration.42. The method of claim claim 1 , claim 1 , wherein said administration comprises intra-muscular administration.52. The method of claim claim 1 , claim 1 , wherein said administration comprises subcutaneous administration.62. The method of claim claim 1 , claim 1 , wherein said administration comprises intra-peritoneal administration.72. The method of claim claim 1 , claim 1 , wherein said administration comprises oral administration. This application is a continuation of U.S. application Ser. No. 10/375,906, filed Feb. 27, 2003, which is hereby incorporated by reference in its entirety.This invention relates to processes for ...

SITAGLIPTIN TANNATE COMPLEX

The present invention provides for a sitagliptin tannate complex or a pharmaceutical compositions or a pharmaceutically acceptable intermediates comprising said complex. This invention also relates to a processes to prepare the sitagliptin tannate complex as well as to methods of using the sitagliptin tannate complex to treat diabetes, obesity and high blood pressure. 1. Sitagliptin tannate complex.2. The sitagliptin tannate complex according to claim 1 , wherein the sitagliptin content is between about 25% and about 75% by weight.3. The sitagliptin tannate complex according to claim 2 , wherein the sitagliptin content is between about 29 and about 33% by weight.4. The sitagliptin tannate complex according to claim 1 , wherein the ratio of sitagliptin to tannic acid is about 3:1 to about 1:4 by weight.5. The sitagliptin tannate complex according to claim 4 , wherein the ratio is about 2:1 by weight.6. A pharmaceutical composition comprising a therapeutically effective amount of the sitagliptin tannate complex according to and an inert carrier.7. The pharmaceutical composition according to that further comprises a therapeutically effective amount of an additional pharmaceutically active ingredient.8. A pharmaceutical intermediate which comprises a therapeutically effective amount of a sitagliptin tannate complex according to claim 1 , a pharmaceutically acceptable polymer claim 1 , and claim 1 , optionally claim 1 , one or more polyols claim 1 , high intensity sweeteners claim 1 , flavorants.9. An oral dosage form which comprises the pharmaceutical intermediate according to .10. The oral dosage form according to claim 9 , which is in the form of a tablet claim 9 , capsule claim 9 , pellet or powder.11. The oral dosage form according to claim 9 , which is in the form of a soft chew claim 9 , medicated gum claim 9 , chewable tablet claim 9 , disintegrating tablet claim 9 , syrup claim 9 , sachet claim 9 , oral film claim 9 , gel or lyosphere.12. The oral dosage form ...

GLUCOCEREBROSIDE TREATMENT OF LIVER DISORDERS

The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings. 135-. (canceled)36. A method for treating auto-immune hepatitis in a mammalian subject , comprising:administering to a mammalian subject having auto-immune hepatitis a pharmaceutical composition comprising a therapeutically effective amount of a β-glucosylceramide,wherein said administration improves the auto-immune hepatitis in said mammalian subject.37. The method of claim 36 , wherein the β-glucosylceramide is soy-derived.38. The method according to claim 36 , wherein said subject is subjected to fasting for a minimum of twelve hours prior to said administration of said β-glucosylceramide.39. The method of claim 38 , wherein the β-glucosylceramide is soy-derived.40. The method of claim 36 , wherein the mammalian subject is a human subject.41. The method of claim 40 , wherein said administering step comprises enteral administration of said β-glucosylceramide.42. The method of claim 40 , wherein said administering step comprises parenteral administration of said β-glucosylceramide.43. The method of claim 37 , wherein the mammalian subject is a human subject.44. The method of claim 43 , wherein said administering step comprises enteral administration of said β-glucosylceramide.45. The method of claim 43 , wherein said administering step comprises parenteral administration of said β-glucosylceramide.46. The method of claim 38 , wherein the mammalian subject is a human subject.47. The method of claim 46 , wherein said administering step comprises enteral administration of said β-glucosylceramide.48. The method of claim 46 , wherein ...

COMPOSITIONS AND METHODS FOR INCREASING LIFESPAN AND HEALTH SPAN

Disclosed herein are compounds, extracts, and active fractions of the plant and methods for increasing longevity and survival potency or for preventing or treating various medical conditions, including diabetes, inflammation, wound healing, bed sores, and ocular disorders. The compounds provided herein can be formulated into pharmaceutical compositions and medicaments that are useful in the disclosed methods. Also provided are the use of the compounds and extracts in preparing pharmaceutical formulations and medicaments 113.-. (canceled)14Geum japonicum.. A method for preventing or treating diabetes in a subject in need thereof , the method comprising administering to the subject an effective amount of an organic extract of15Geum japonicum.. A method for preventing or treating an ocular disease or condition in a subject in need thereof , the method comprising administering to the subject an effective amount of an organic extract of17Geum japonicum.. A method for enhancing wound healing in a subject having a wound , the method comprising administering to the subject an effective amount of an organic extract of18. The method of claim 17 , wherein the wound is a bed sore.19. The method of claim 17 , wherein the organic extract is an ethanol extract.20. The method of claim 17 , wherein the organic extract is a methanol extract.21. The method of claim 17 , wherein the subject is a human.22. The method of claim 17 , wherein the extract of is administered orally.23. The method of claim 17 , wherein the extract is administered by subcutaneous injection claim 17 , intramuscular injection claim 17 , or intravenous infusion.24. The method of wherein the extract is administered in an amount of from 0.01 mg/kg/day to 2000 mg/kg/day.25. The method of claim 17 , wherein the effective amount of the extract is a formulation comprising the extract and a pharmaceutically acceptable carrier. The present application claims priority to U.S. Provisional Application No. 61/186,709, filed ...

METHODS OF GANGLIOSIDE PRODUCTION

The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g. GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided. 1. A method of producing a ganglioside in a cell , comprising:(a) treating said cell with chloroquine to accumulate said ganglioside; wherein said cell is selected from the group consisting of an immortalized cell, a stromal cell, and a fibroblast;', 'wherein said cell is not a PC12 cell, an HT22 cell, a brain cell from a sheep afflicted with gangliosidosis, and fibroblast cell from sheep afflicted with gangliosidosis., '(b) isolating said ganglioside, quantifying said ganglioside, or both, from said chloroquine-treated cell;'}2. The method of claim 1 , wherein said cell is selected from the group consisting of a neuroblastoma cell claim 1 , a Chinese hamster ovary cell (CHO) claim 1 , a human embryonic kidney cell (HEK) claim 1 , a stromal cell claim 1 , and a fibroblast cell.3. The method of claim 2 , wherein said cell is a CHO) cell claim 2 , wherein said CHO cell is a CHO-K1 cell.4. The method of claim 2 , wherein said cell is a HEK cell claim 2 , wherein said HEK cell is a HEK293 cell.5. The method of claim 2 , wherein said cell is a fibroblast cell.6. The method of claim 5 , wherein said fibroblast cell is a dermal fibroblast cell.7. The method of claim 5 , wherein said fibroblast cell is a fibroblast from a human with GM1 gangliosidosis.8. The method of claim 2 , wherein said cell is a neuroblastoma cell.9. The method of claim 8 , wherein said ...

USE OF GINSENOSIDE M1 FOR PREVENTING OR TREATING GOUT

The present invention discloses a new use of ginsenoside M1 for treating or preventing gout. 1. A method of treating gout in a subject in need thereof comprising administering to the subject an amount of ginsenoside M1 effective to treat the subject.2. The method of claim 1 , wherein the method of treating is effective in inhibiting monosodium urate crystals (MSU) or calcium pyrophosphate dehydrate (CPPD)-induced activation of NLRP3 inflammasome.3. The method of claim 1 , wherein the method of treating is effective in inhibiting MSU or CPPD-induced interleukin 1β production through NLRP3 inflammasome.4. The method of claim 1 , wherein the ginsenoside M1 is administered by parenteral or enteral route.58.-. (canceled) This application claims the benefit of U.S. provisional application No. 62/134,227, filed Mar. 17, 2015, the entire content of which is incorporated herein by reference.The present invention relates to a new use of ginsenoside M1 for treating or preventing gout.Gout is a kind of arthritis caused by a buildup of uric acid crystals in the joints. Symptoms include pain, swelling and shiny redness over the affected joints.Ginsenosides, the main active ingredients of ginseng, are known to have a variety of pharmacological activities, e.g. antitumor, antifatigue, antiallergic and antioxidant activities. Ginsenosides share a basic structure, composed of gonane steroid nucleus having 17 carbon atoms arranged in four rings. Ginsenosides are metalized in the body, and a number of recent studies suggest that ginsenoside metabolites, rather than naturally occurring ginsenosides, are readily absorbed in the body and act as the active components. Among them, ginsenoside M1 is known as one metabolite of protopanaxadiol-type ginsenosides via the gypenoside pathway by human gut bacteria. Until now, no prior art references report the effect of ginsenoside M1 in treatment of gout.In the present invention, it is unexpected found that ginsenoside M1 is effective in ...

USE OF GINSENOSIDE M1 FOR PREVENTING OR TREATING SILICOSIS

The present invention discloses a new use of ginsenoside M1 for treating or preventing silicosis. 1. A method of treating silicosis in a subject in need thereof comprising administering to the subject an amount of ginsenoside M1 effective to treat the subject.2. The method of claim 1 , wherein the method of treating is effective in inhibiting silica crystal-induced activation of NLRP3 inflammasome.3. The method of claim 1 , wherein the method of treating is effective in inhibiting silica crystal-induced interleukin 1β production through NLRP3 inflammasome.4. The method of claim 1 , wherein the ginsenoside M1 is administered by parenteral or enteral route.58.-. (canceled) This application claims the benefit of U.S. provisional application number 62/134,236, filed Mar. 17, 2015, the entire content of which is incorporated herein by reference.The present invention relates to a new use of ginsenoside M1 for treating or preventing silicosis.Silicosis is a type of lung disease that is caused by inhaling silica particles, usually from working in mines and quarries and in some other occupations such as construction, foundry-work, ceramics and glass-making. Silica particles affects lung's normal function. The symptoms include shortness of breath, severe cough and weakness.Ginsenosides, the main active ingredients of ginseng, are known to have a variety of pharmacological activities, e.g. antitumor, antifatique, antiallergic and antioxidant activities. Ginsenosides share a basic structure, composed of gonane steroid nucleus having 17 carbon atoms arranged in four rings. Ginsenosides are metalized in the body, and a number of recent studies suggest that ginsenoside metabolites, rather than naturally occurring ginsenosides, are readily absorbed in the body and act as the active components. Among them, ginsenoside M1 is known as one metabolite of protopanaxadiol-type ginsenosides via the gypenoside pathway by human gut bacteria. Until now, no prior art references report the ...

DRUG HAVING REGULATORY CELL LIGAND CONTAINED IN LIPOSOME

A liposome containing a regulatory cell ligand such as α-galactosyl ceramide or β-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc. 111-. (canceled)12. A pharmaceutical composition , comprising liposomes comprising KRN7000.13. A method of preventing or treating graft versus host disease (GVHD) claim 12 , comprising administering the pharmaceutical composition of to a subject in need of such prevention or treatment.14. A method of preventing or treating rejection by a transplant patient claim 12 , comprising administering the pharmaceutical composition of to such patient.15. A method of preventing or treating autoimmune diseases claim 12 , comprising administering the pharmaceutical composition of to a subject in need of such prevention or treatment.16. A method of preventing or treating an allergic disease claim 12 , comprising administering the pharmaceutical composition of to a subject in need of such prevention or treatment.17. The method of claim 16 , wherein the allergic disease is selected from the group consisting of atopic bronchial asthma claim 16 , allergic rhinitis claim 16 , pollinosis claim 16 , and atopic dermatitis. The present invention relates to a drug having a regulatory cell ligand contained in a liposome, and more particularly relates to a drug for immune diseases such as allergic diseases and autoimmune diseases.Immune diseases such as allergic diseases, autoimmune diseases and graft-versus-host diseases (GVHD) are the disease caused by abnormality or incompatibility of the immune system. Among them, patients with some illness of allergic disease tend to increase year by year, and it has been reported that 70% of Japanese people have already affected with some allergic disease. A category of the allergic diseases is broad and includes asthma, atopic dermatitis, pollinosis, food allergy and allergodermia. Many of the patients with allergy are known to develop various allergic ...

COMPOSITION AND PREPARATION AND USES THEREOF FOR PREVENTING AND TREATING DIABETES

Disclosed is a composition for use in the prevention, treatment, and management of diabetes in human and animal subjects that contains 2,3,5,4-tetrahydroxystilbene 2-O-b-glucopyranoside collected from one or more plants selected from the group consisting of genera of plants. 1Fallopia. A composition for use in the prevention , treatment , and management of diabetes in human and animal subjects , comprising 2 ,3 ,5 ,4-tetrahydroxystilbene 2-O-b-glucopyranoside (stilbene glycoside) collected from one or more plants selected from the group consisting of genera of plants.2. The composition of claim 1 , wherein the stilbene glycoside comprises cis-stilbene glycoside and/or trans-stilbene glycoside.3. The composition of claim 1 , wherein the stilbene glycoside comprises 0-99 wt % cis-stilbene glycoside and 100-1 wt % trans-stilbene glycoside.4. The composition of claim 3 , wherein the cis-stilbene glycoside is derived from the trans-stilbene glycoside by exposure to light.5. The composition of claim 4 , wherein the light is UV light.6Polygonum multiflorum. The composition of claim 1 , wherein the plant is (PM).7. The composition of claim 5 , wherein the composition is prepared by:crushing dried roots of PM to powder;extracting the PM powder with an ethanol solution under the room temperature for at least 2 days to obtain an ethanolic extract, the ratio of solution to solid being about 1:10 (v/w);evaporating and concentrating the ethanolic extract under reduced pressure to obtain a dried extract;subjecting the dried extract to macroporous resin chromatography, followed by eluting the resin with ethanol solutions of different concentrations to obtain a first eluant; andevaporating and drying the first eluant under reduced pressure to obtain PM extract powder.8. The composition of claim 6 , wherein the composition is further prepared by:dissolving the PM extract powder in an aqueous solution and placing the solution under light over night; andsubjecting the light-treated ...

Treatments for Alzheimer's disease

New Treatments for Alzheimer's Disease utilizing gangliosides, glycoproteins, and replacement of non-mutant enzymes and chaperones, as well as enzyme up-regulation accomplished by a number of gene-therapy methodologies. 1. The method of using gangliosides , administered intra-muscularly or intravenously , to restore neuronal cell dysfunction , prevent cell death and reduce the levels of aggregated amyloid proteins (plaques) and phosphorylated tau (Tangles) in patients with Alzheimer's Disease. This use of either natural or synthetic gangliosides prevents Alzheimer's Disease from progressing and restores the functions of the surviving neurons.2. The method as set forth in wherein the gangliosides are naturally occurring gangliosides such as GM1 claim 1 , GD1 claim 1 , GT1 and related structures.3. The method as set forth in wherein purified GM1 is dissolved in isotonic salt solution and is used by intravenous or intramuscular routes at total daily concentrations from 10 mg/Kg to 50 mg/Kg of body weight. This treatment is given on daily basis for one week and then repeated every other week.4. The method as set forth in wherein the gangliosides are synthetic gangliosides that contain silalylated sugars attached to a carrier long chain lipid. As an example claim 1 , LIGA20 is used as a solution claim 1 , intravenously or intramuscularly at concentrations from 2 to 30 mg/Kg. The treatment schedule is similar to that of GM1.5. The method of using by Intramuscular or intravenous administration claim 1 , natural or synthetic glycoproteins that carry sialic acid to treat Alzheimer's Disease.6. The method of wherein the glycoproteins are natural glycoproteins such as NCAM (Neuronal Cell Adhesion Molecules).7. The method of wherein the glycoproteins are synthetic sialylated glycoproteins. These molecules are synthesized by the O-linking of sialylated N-acetylgalactosamine (GaINAc) to serine or threonine claim 5 , components in synthetic peptides. To assure deposition on ...

COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2

Pharmaceutical dosage forms useful for improving the cardiovascular and/or metabolic health of patients, particularly those suffering from type 2 diabetes, are disclosed, as well as methods of their manufacture.

ATTRACTANT FOR BONE MARROW STEM CELLS AND METHOD FOR ATTRACTING BONE MARROW STEM CELLS

Provided are an attractant for bone marrow stem cells containing at least one of cinnamtannin B1 and pentagalloylglucose, and a method for attracting bone marrow stem cells in which bone marrow stem cells are attracted by the attractant. 1. An attractant for bone marrow stem cells , comprisingat least one of cinnamtannin B1 and pentagalloylglucose.2. A method for attracting bone marrow stem cells , comprisingattracting the bone marrow stem cells by an attractant for bone marrow stem cells containing at least one of cinnamtannin B1 and pentagalloylglucose. This application claims priority to Japanese Patent Application No. 2012-139442, the disclosure of which is invoked herein in its entirety. The contents of the application in Japan are incorporated herein by referenceThe present invention relates to an attractant for bone marrow stem cells and a method for attracting bone marrow stem cells.Bone marrow stem cells are known as cells that are generated in bone marrow and have not yet undifferentiated, and that can differentiate into cells of various body tissues. Further, attention has been given to bone marrow stem cells as being capable of recovering a lost function of a tissue by differentiating into cells of the tissue under the influence of a differentiation inducer that induces differentiation.Specifically, attention has been given to bone marrow stem cells as being capable of differentiating into tissue cells under the influence of a differentiation inducer, for example, after they migrate from the bone marrow to an inflamed tissue or a damaged tissue through the bloodstream.Conventionally, various differentiation inducers that are capable of causing differentiation of bone marrow stem cells into various cells are known. For example, a fibroblast growth factor (Fibroblast Growth Factor: FGF) and a platelet-derived growth factor (Platelet-Derived Growth Factor: PDGF) that can cause bone marrow stem cells to differentiate into heart muscle cells are known (Patent ...

PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS

The present embodiments relate to methods for the prevention and treatment of inflammatory conditions such as alcoholic liver disease (ALD). More specifically the present embodiments relate to the prevention and treatment of ALD through the administration of an Retinoic Acid Receptor (RAR) agonist. Some embodiments relate to use of tazarotene in the prevention and treatment of alcohol-induced liver injury, alcohol-related liver disease, fatty liver disease, hepatic steatosis, alcoholic hepatitis or alcoholic cirrhosis. 124-. (canceled)25. A method for treating or preventing at least one inflammatory condition in a patient comprising administering to the patient an amount of a RARγ agonist sufficient to inhibit activation of type I NKT cells.26. The method of wherein the inflammatory condition is selected from the group consisting of: fatty liver disease claim 25 , alcohol induced hepatitis claim 25 , non-alcoholic steatosis hepatitis claim 25 , cirrhosis claim 25 , fulminating cirrhosis claim 25 , idiopathic hepatitis claim 25 , viral-induced hepatitis (A claim 25 , B claim 25 , C and other) claim 25 , inflammatory hepatitis associated with hepato-biliary carcinoma claim 25 , multiple sclerosis claim 25 , type 1 diabetes claim 25 , ischemic reperfusion injury claim 25 , solid organ transplantation claim 25 , systemic lupus erythematosus claim 25 , rheumatoid arthritis claim 25 , amyotrophic lateral sclerosis claim 25 , and inflammatory bowel disease (Crohn's and colitis).27. The method of claim 25 , wherein the RARγ agonist comprises tazarotene.28. The method of claim 25 , further comprising administering an amount of sulfatide or synthetic sulfatide analog sufficient to activate type II NKT cells.31. The method of claim 28 , wherein a synthetic sulfatide analog is administered.32. The method of claim 25 , wherein the patient is at risk of chemical liver damage from prescription drugs or drugs of abuse claim 25 , and wherein inhibiting activation of type I NKT cells ...

AGI-134 COMBINED WITH A CHECKPOINT INHIBITOR FOR THE TREATMENT OF SOLID TUMORS

A method of treating a tumor in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of: 1. A method of treating a tumor in a subject , comprising administering to the subject a therapeutically effective amount of:i) Pembrolizumab; and{'figref': {'@idref': 'DRAWINGS', 'FIG. 1'}, 'ii) a lipid having a structural formula as illustrated in (AGI-134);'}thereby treating the tumor in the subject.2. The method of claim 1 , wherein said Pembrolizumab and said AGI-134 are in separate formulations.3. The method of claim 2 , wherein said Pembrolizumab is administered following administration of said AGI-134.4. The method of claim 1 , wherein said Pembrolizumab and said AGI-134 are administered not more than two hours apart.5. The method of claim 1 , further comprising administering to said subject Pembrolizumab in the absence of said AGI-134 following said administering of Pembrolizumab and said AGI-134.6. The method of claim 1 , wherein said Pembrolizumab is administered intravenously or intratumorally.7. (canceled)8. The method of claim 1 , wherein said AGI-134 and said Pembrolizumab are administered once every three weeks for four cycles.9. The method of claim 5 , wherein said Pembrolizumab is administered in the absence of said AGI-134 once every three weeks for up to one year of treatment.10. The method of claim 1 , wherein a dose of AGI-134 per administration is between 25 mg-200 mg.11. The method of claim 1 , wherein a dose of Pembrolizumab per administration is 100 mg 500 mg per administration.12. The method of claim 1 , wherein a dose of Pembrolizumab per administration is 200 mg per administration.13. A method of treating a tumor in a subject claim 1 , comprising:i) intratumorally administering to the subject between 25-200 mg of AGI-134;ii) intravenously administering to the subject 200 mg of Pembrolizumab; wherein said Pembrolizumab and said AGI-134 are administered not more than two hours apart, wherein said ...

NON-TOXIC AGENT FOR A BROAD-SPECTRUM, BACTERICIDAL OR BACTERIOSTATIC TREATMENT OF ANTIBIOTIC-RESISTANT BACTERIA IN ANIMALS

Methods and compositions are provided for a broad-spectrum, bactericidal or bacteriostatic treatment of antibiotic-resistant bacteria in animals with a non-toxic agent. The teachings include bactericidal or bacteriostatic treatment of spore-forming, anaerobic antibiotic-resistant bacteria. And, the compositions and methods provided herein can at least inhibit the onset of, inhibit the growth of, inhibit the germination of, or kill the antibiotic-resistant bacteria. Such antibiotic-resistant bacteria include, but are not limited to, , and 1. A method of treating a subject that is hosting an antibiotic-resistant bacteria , the method comprising:administering an effective amount of a formulation to a subject that is hosting an antibiotic-resistant bacteria, the formulation having a water soluble tannin combined with hydrogen peroxide in a pharmaceutically acceptable excipient;wherein,the tannin has a molecular weight ranging from about 170 Daltons to about 4000 Daltons;the tannin:peroxide weight ratio ranges from about 1:1000 to about 10:1; and,the formulation at least inhibits the growth of the antibiotic-resistant bacteria in the subject when compared to a second subject in a control group also hosting the antibiotic-resistant bacteria in which the formulation was not administered.2Clostridium difficile.. The method of claim 1 , wherein the antibiotic-resistant bacteria is3Enterococcus faecalis.. The method of claim 1 , wherein the antibiotic-resistant bacteria is4Staphylococcus aureus.. The method of claim 1 , wherein the antibiotic-resistant bacteria is5Klebsiella pneumoniae.. The method of claim 1 , wherein the antibiotic-resistant bacteria is6. The method of claim 1 , wherein the tannin is a catechin.7. The method of claim 1 , wherein the tannin is gallic acid claim 1 , epigallic acid claim 1 , or a combination thereof.8. The method of claim 1 , wherein the tannin is an ellagitannin.9. The method of claim 1 , wherein the tannin is punicalagin.10. The method of ...

NUTRITIONAL COMPOSITIONS CONTAINING A NEUROLOGIC COMPONENT AND USES THEREOF

The present disclosure relates to nutritional compositions comprising a neurologic component, wherein, the neurologic component may promote brain and nervous system development and further provide neurological protection and repair. The neurologic component may include phosphatidylethanolamine, sphingomyelin, cytidine diphosphate-choline, ceramide, uridine, at least one ganglioside, and mixtures thereof. The disclosure further relates to methods of promoting brain and nervous system health by providing said nutritional compositions to target subjects, which includes pediatric subjects. 1. A nutritional composition comprising:(i) a carbohydrate source;(ii) a protein source;(iii) a fat source;(iv) lactoferrin; and(v) a neurologic component comprising lutein and a nutrient selected from the group consisting of PE, sphingomyelin, CDP-choline, ceramide, uridine, at least one ganglioside and combinations of one or more thereof, wherein the neurologic component promotes neurogenesis when provided to a target subject.2. The nutritional composition of claim 1 , wherein PE is present in an amount from about 3.7 mg/100 kcal to about 37 mg/100 kcal.3. The nutritional composition of claim 1 , wherein sphingomyelin is present in an amount from about 0.15 mg/100 kcal to about 73 mg/100 kcal.4. The nutritional composition of claim 1 , wherein CDP-choline is present in an amount from about 7 mg/100 kcal to about 295 mg/100 kcal.5. The nutritional composition of claim 1 , wherein ceramide is present in an amount from about 2.2 mg/100 kcal to about 22 mg/100 kcal.6. The nutritional composition of claim 1 , wherein uridine is present in an amount from about 0.15 mg/100 kcal to about 37 mg/100 kcal.7. The nutritional composition of claim 1 , wherein ceramide is selected from the group consisting of N-octanoyl-D-threo-sphingosine claim 1 , N—(R claim 1 ,S) alpha-Hydroxydodecanoyl-D-erythro-sphingosine claim 1 , and lactosylceramide.8. The nutritional composition of claim 1 , further ...

Pharmaceutical Composition and Health Functional Food Containing Red Ginseng Concentrate Having Enhanced Compound K for Preventing and Treating Non-alcoholic Fatty Liver Disease

The present invention relates to a pharmaceutical composition and a health functional food composition for preventing and treating non-alcoholic fatty liver disease, which comprises red concentrate having enhanced Compound K as an effective ingredient by using an enzyme conversion technique. 1ginseng. A pharmaceutical composition for treating and preventing non-alcoholic fatty liver disease , which comprises red concentrate having enhanced Compound K.2ginseng. The pharmaceutical composition according to claim 1 , wherein the red concentrate having enhanced Compound K are comprised in an amount of 0.1 to 99% by weight to the total weight of the pharmaceutical composition.3. The pharmaceutical composition according to claim 1 , wherein the content of the Compound K is enhanced in a range of 0.5 to 1.5 mg/g.4ginseng. A health functional food comprising red concentrate having enhanced Compound K as an effective ingredient.5ginseng. The health functional food according to claim 4 , wherein the red concentrate having enhanced Compound K is comprised in an amount of 0.1 to 99% by weight to the total of weight of the health functional food.6. The health functional food according to claim 1 , wherein the content of the Compound K is enhanced in a range of 0.5 to 1.5 mg/g. This application claims priority to Korean Application Serial No. 10-2014-0156917, filed Nov. 12, 2014, the content of which is incorporated here by reference in its entirety.The present invention relates to a pharmaceutical composition containing a red concentrate having enhanced compound K as an effective ingredient for preventing and treating non-alcoholic fatty liver disease and a health functional food containing the red contrate having enhanced compound K as the effective ingredient, for preventing and improving non-alcoholic fatty liver disease.(C. A. Mayer) is a plant belonging to genus of , and has been used for a drug in China from B.C., and has been used for a trade and drug from the period of ...

Pharmaceutical composition comprising a proton pump inhibitor and a prebiotic for the treatment of ulcerous lesions of the stomach and duodenum

A pharmaceutical composition including proton pump inhibitors and prebiotics is proposed for the treatment of gastric and duodenal ulcer, this allowing effective ulcer treatment and eradication of H. pylori from the gastric and duodenal mucosa to be carried out without using wide-spectrum antibiotics. The comprehensive treatment of ulcer disease associated with a helicobaterial infection using a pharmaceutical composition of a PPI and a prebiotic makes it possible, in conditions of an elevated pH of the stomach contents, actively to stimulate the growth of lactobacilli in the upper sections of the gastrointestinal tract, including the duodenum, and substantially to increase the titre of lactobacilli, which are antagonists of H. pylori, which greatly improves the effectiveness of the ulcer treatment. 1. A method for treating a gastric and/or duodenal ulcer in a patient , comprising the following step:stimulating of growth of patient's own bifidobacteria and lactobacilli in a duodenum via delivering the prebiotic to a patient's stomach and duodenum; andreducing gastric acid production by inhibiting of H. pylori in the duodenum by delivering a proton-pump inhibitor to the duodenum;thus achieving the ulcer treatment without using antibiotics.2. The method of claim 1 , wherein inhibiting of H. pylori in the duodenum is at least 10× to the initial number.3. The method of claim 1 , wherein the prebiotic being 40-95% by weight of a composition claim 1 , comprising the prebiotic and the proton-pump inhibitor.4. The method of claim 1 , wherein the proton pump inhibitor contains 10-120 mg of omeprazole.5. The method of claim 1 , wherein the proton pump inhibitor contains 20-800 mg of pantoprazole.6. The method of claim 1 , wherein the proton pump inhibitor contains 10-600 mg of lansoprazole.7. The method of claim 1 , wherein the proton pump inhibitor contains 10-200 mg of rabeprazole.8. The method of claim 1 , wherein the proton pump inhibitor contains 20-240 mg of ...

ANTI-VIRAL COMBINATION THERAPY

The present invention provides methods and compounds for treating viral infections using combinations modulators of an HCV-associated component and modulators of host cell enzymes. The present invention also provides methods and compounds for treating viral infections using combinations of modulators of host cell enzymes and other agents that work, at least in part by modulating hos factors. 1. A method of treating or preventing HCV infection comprising administering to a subject in need thereof a therapeutically effective amount of (i) a compound that is an inhibitor of acetyl-CoA carboxylase (ACC) or a prodrug thereof , or pharmaceutically acceptable salt or ester of said compound or prodrug and (ii) a compound that is a modulator of an HCV-associated component or a prodrug thereof , or pharmaceutically acceptable salt or ester of said compound or prodrug.2. The method of claim 1 , wherein the inhibitor of ACC inhibits ACC1 claim 1 , ACC2 claim 1 , or both ACC1 and ACC2.4. The method of claim 3 , wherein the ACC inhibitor is TOFA.6. The method of claim 5 , wherein the ACC inhibitor is CP-610431.7. The method of claim 5 , wherein the ACC inhibitor is CP-640186.8. The method of claim 1 , wherein an immunomodulator is also administered to the subject.9. The method of claim 8 , wherein the immunomodulator is one or more of Pegasys claim 8 , Roferon-A claim 8 , Pegintron claim 8 , Intron A claim 8 , Albumin IFN-α claim 8 , locteron claim 8 , Peginterferon-λ claim 8 , omega-IFN claim 8 , medusa-IFN claim 8 , belerofon claim 8 , infradure claim 8 , Interferon alfacon-1 claim 8 , and Veldona.10. The method of claim 1 , wherein one or more of ribavirin or a ribavirin analog selected from taribavirin claim 1 , mizoribine claim 1 , merimepodib claim 1 , mycophenolate mofetil claim 1 , and mycophenolate is also administered to the subject.11. A method of treating or preventing HCV infection comprising administering to a subject in need thereof a therapeutically effective ...

GLYCOLIPIDS AS TREATMENT FOR DISEASE

This invention provides compounds, compositions, and methods for treating a disorder selected from cancer, hyperinsulinemia, hypoglycemia, hyperinsulinemia with hypoglycemia, atypical Parkinson's disease, Huntington's disease, multiple systems atrophy, GM3 synthase deficiency, GM2 synthase deficiency or tauopathy. 2. The method of claim 1 , wherein the disorder is selected from cancer claim 1 , hyperinsulinemia claim 1 , hypoglycemia claim 1 , hyperinsulinemia with hypoglycemia claim 1 , Huntington's disease claim 1 , multiple systems atrophy claim 1 , GM3 synthase deficiency claim 1 , GM2 synthase deficiency or tauopathy.3. The method of claim 1 , wherein the glycolipid is selected from the group consisting of LacCer claim 1 , GA2 claim 1 , GA1 claim 1 , GM1b claim 1 , GD1c claim 1 , GD1α claim 1 , GM3 claim 1 , GM2 claim 1 , GM1a claim 1 , GD1a claim 1 , GT1a claim 1 , GT1α claim 1 , GD3 claim 1 , GD2 claim 1 , GD1b claim 1 , GT1b claim 1 , GQ1b claim 1 , GQ1bα claim 1 , GT3 claim 1 , GT2 claim 1 , GT1c claim 1 , GQ1c claim 1 , GP1c claim 1 , and GP1cα.4. The method of claim 2 , wherein the affected disorder has a deficiency in tissue level of any one or more of the gangliosides selected from GA2 claim 2 , GA1 claim 2 , GM1b claim 2 , GD1c claim 2 , GD1α claim 2 , GM3 claim 2 , GM2 claim 2 , GM1a claim 2 , GD1a claim 2 , GT1a claim 2 , GT1α claim 2 , GD3 claim 2 , GD2 claim 2 , GD1b claim 2 , GT1b claim 2 , GQ1b claim 2 , GQ1bα claim 2 , GT3 claim 2 , GT2 claim 2 , GT1c claim 2 , GQ1c claim 2 , GP1c claim 2 , and GP1cα.5. The method of claim 1 , wherein the saccharide moiety of a ganglioside selected from GM3 claim 1 , GM2 claim 1 , GM1a claim 1 , GD1a claim 1 , GT1a claim 1 , or GT1α.6. The method of claim 1 , wherein the saccharide is a mono- claim 1 , di- claim 1 , tri- claim 1 , tetra- claim 1 , penta- claim 1 , hexa- claim 1 , or hepta-saccharide.9. The method of claim 1 , wherein the fatty acid has at least one cis double bond.10. The method of any one of ...

AGENT DELIVERY SYSTEM

The invention provides an agent delivery system comprising an agent preparation encapsulated within a membrane composition. The invention further provides a membrane composition comprising a ganglioside and lipid for encapsulating agents, and processes for preparing the membrane compositions. The invention further provides agent preparations encapsulated within the membrane compositions, including a plurality of individual particles wherein each particle contains agent preparation individually encapsulated within membrane composition. The invention also provides processes for preparing encapsulated agent preparations or individual particles of encapsulated agent preparations. The agents may be biologically active including hydrophilic, hydrophobic, small molecule or large molecule therapeutic agents. The invention further provides pharmaceutical compositions comprising encapsulated agent preparations or individual particles of encapsulated agent preparations. The invention further provides methods for delivery of the encapsulated agent preparations or individual particles of encapsulated agent preparations to a subject, including oral delivery of large molecule therapeutic agents to the lymphatic system, blood circulatory system, and/or targeted delivery to cells, tissues or organs. 1. An agent preparation encapsulated within a membrane composition , wherein the agent preparation comprises an agent , and the membrane composition comprises a lipid and ganglioside , the ganglioside having a lipophilic domain and a hydrophilic domain , wherein the hydrophilic domain comprises (i) a mono- , di- , tri- , or tetra-saccharide residue , and (ii) one to four sialic acid residues linked to the saccharide residue , the membrane composition having an outer surface , wherein at least a portion of the hydrophilic domain is present on the outer surface.2. The agent preparation encapsulated within the membrane composition of claim 1 , which exists as a plurality of individual ...

USE OF BIOSURFACTANT

An object is to provide a novel means for ameliorating mastitis or improving milk production. An ameliorating or therapeutic agent for mastitis that contains a biosurfactant, or a milk production promoting agent that contains a biosurfactant, is provided. 1. An ameliorating or therapeutic agent for mastitis comprising a biosurfactant.2. A milk production promoting agent comprising a biosurfactant.3. The agent according to claim 2 , which is for a ruminant.4. The agent according to claim 2 , which is topically applied to an udder or breast.5. The agent according to claim 4 , wherein the topical application is continued at a frequency of at least once a day for at least 3 days.6. A method for ameliorating or treating mastitis claim 4 , comprising topically applying a biosurfactant to an udder of a ruminant.7. A method for promoting milk production claim 4 , comprising topically applying a biosurfactant to an udder of a ruminant.8. The method for promoting milk production according to claim 7 , wherein the topical application is performed at a frequency of at least once a day.9. The method for promoting milk production according to claim 7 , wherein the topical application is performed at a frequency of at least once a day for at least 3 days.10. The method for ameliorating or treating mastitis according to claim 6 , wherein the topical application is performed at a frequency of at least once a day for at least 3 days.11. The agent according to claim 1 , which is for a ruminant.12. The agent according to claim 1 , which is topically applied to an udder or breast.13. The agent according to claim 12 , wherein the topical application is continued at a frequency of at least once a day for at least 3 days. Techniques for ameliorating or treating mastitis and promoting milk production are disclosed.Among dairy cow diseases, mastitis is a disease that develops in the mammary gland directly related to the productivity of milk; therefore, its economic impact is very large. As a ...

GM-CSF-PRODUCING T-CELL CONTROL AGENT AND Th1/Th2 IMMUNE BALANCE REGULATOR

The present invention provides a GM-CSF-producing T-cell control agent comprising a glycolipid compound represented by the following formula (I) or a salt thereof as an active ingredient: 134.-. (canceled)36. The method according to claim 35 , wherein the glycolipid compound is administered in an amount of 0.05 mg to 30 mg per dosage to a human subject in need thereof.38. The method according to claim 35 , wherein Rrepresents —CH(OH)—CH—.39. The method according to claim 35 , wherein Rand Reach represent a hydrogen atom claim 35 , x is 11 to 23 claim 35 , and z is 0.40. The method according to claim 35 , wherein the glycolipid compound is orally administered to a human subject in need thereof.42. The method according to claim 41 , wherein the glycolipid compound is administered in an amount of 0.05 mg to 30 mg per dosage to a human subject in need thereof.44. The method according to claim 41 , wherein Rrepresents —CH(OH)—CH—.45. The method according to claim 41 , wherein Rand Reach represent a hydrogen atom claim 41 , x is 11 to 23 claim 41 , and z is 0.46. The method according to claim 41 , wherein the glycolipid compound is orally administered to a human subject in need thereof.47. The method according to claim 41 , wherein the diseases caused by increase in GM-CSF concentration are multiple sclerosis claim 41 , chronic organ inflammation claim 41 , or rheumatoid arthritis.49. The method according to claim 48 , wherein the glycolipid compound is administered in an amount of 0.05 mg to 30 mg per dosage to a human subject in need thereof.51. The method according to claim 48 , wherein Rrepresents —CH(OH)—CH—.52. The method according to claim 48 , wherein Rand Reach represent a hydrogen atom claim 48 , x is 11 to 23 claim 48 , and z is 0.53. The method according to claim 48 , wherein the glycolipid compound is orally administered to a human subject in need thereof. The present invention relates to a GM-CSF-producing T-cell control agent comprising a α- ...

FUCOSYLLACTOSE AS BREAST MILK IDENTICAL NON-DIGESTIBLE OLIGOSACCHARIDE WITH NEW FUNCTIONAL BENEFIT

The invention concerns nutritional compositions with fucosyllactose for use in stimulation of NK cells. The composition is suitable for infants. 111-. (canceled)12. A method of stimulating natural killer (NK) cell activity and/or NK cell proliferation , comprising administering to a subject in need thereof an enteral composition comprising fucosyllactose , wherein the composition is not human milk.13. The method according to claim 12 , wherein subject is an infant HIV patient claim 12 , elderly and/or oncology patient.14. The method according to claim 12 , wherein the subject is an infant.15. The method according to claim 12 , wherein the composition additionally comprises at least one of beta-galacto-oligosaccharides claim 12 , fructo-oligosaccharides and uronic acid oligosaccharides.16. The method according to claim 12 , wherein the fucosyllactose is 2′-fucosyllactose.17. The method according to claim 12 , wherein the composition comprises 0.07 to 1 wt % fucosyllactose based on dry weight of the composition.18. The method according to claim 12 , wherein the composition comprises 5 to 50% protein claim 12 , 15 to 85% digestible carbohydrates and 5 to 50% fat based on total energy.19. A method of treating and/or preventing viral infections claim 12 , comprising administering to a subject in need thereof an enteral composition comprising fucosyllactose claim 12 , wherein the composition is not human milk.20. The method according to claim 19 , wherein subject is an infant HIV patient claim 19 , elderly and/or oncology patient.21. The method according to claim 19 , wherein the subject is an infant.22. The method according to claim 19 , wherein the composition additionally comprises at least one of beta-galacto-oligosaccharides claim 19 , fructo-oligosaccharides and uronic acid oligosaccharides.23. The method according to claim 19 , wherein the fucosyllactose is 2′-fucosyllactose.24. The method according to claim 19 , wherein the composition comprises 0.07 to 1 wt % ...

METHODS FOR INHIBITING ADVANCED GLYCATION END PRODUCT PRODUCTION, INHIBITING FIBROBLAST APOPTOSIS, AND/OR PROMOTING HUMAN FIBROBLAST-COLLAGEN GRATING FORMULATION USING CHERRY BLOSSOM AND CHERRY LEAF EXTRACT

Disclosed is an AGE production inhibitor or the like, which effectively inhibits the production of an advanced glycation end product (AGE), while having improved biological safety. Specifically disclosed is an AGE production inhibitor or the like, which contains en extract of cherry tree (preferably blossoms or leaves thereof) and/or a processed product of the extract as an active substance. The AGE production inhibitor or the like contains, as an active substance, at least one compound that is selected from among 1-O-(E)-Caffeoyl-β-D-glucopyranoside, 1-O-(E)-Coumaroyl-β-D-glucopyranoside, 1-O-(E)-Cinnamoyl-β-D-glucopyranoside, Kaempferol 3-O-β-D-glucopyranoside, Quercetin 3-O-β-D-glucopyranoside, Kaempferol 3-O-(6″-malony)-β-D-glucopyranoside, and Quercetin 3-O-(6″-malony)-β-D-glucopyranoside. 133-. (canceled)34. A method of inhibiting advanced glycation end product production in a person comprising the step of administering an effective amount of a cherry blossom or cherry leaf extract comprising each of 1-O-(E)-Caffeoyl-β-D-glucopyranoside , 1-O-(E)-Coumaroyl-β-D-glucopyranoside , 1-O-(E)-Cinnamoyl-β-D-glucopyranoside , Kaempferol 3-O-β-D-glucopyranoside , Quercetin 3-O-β-D-glucopyranoside , Kaempferol 3-O-(6″-malony)-β-D-glucopyranoside , and Quercetin 3-O-(6″-malony)-β-D-glucopyranoside to the person for inhibiting of advanced glycation end product production.35. The method of claim 34 , wherein an agent is administered to the person and the cherry blossom or cherry leaf extract is an active substance of the agent.36. A method of inhibiting fibroblast apoptosis in a person comprising the step of administering an effective amount of a cherry blossom or cherry leaf extract comprising each of 1-O-(E)-Caffeoyl-β-D-glucopyranoside claim 34 , 1-O-(E)-Coumaroyl-β-D-glucopyranoside claim 34 , 1-O-(E)-Cinnamoyl-β-D-glucopyranoside claim 34 , Kaempferol 3-O-β-D-glucopyranoside claim 34 , Quercetin 3-O-β-D-glucopyranoside claim 34 , Kaempferol 3-O-(6″-malony)-β-D- ...

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

The present invention relates to methods and pharmaceutical compositions for the treatment of acute exacerbation of chronic obstructive pulmonary disease. In particular, the present invention relates to a method of treating acute exacerbation of chronic obstructive pulmonary disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one NKT cell agonist. 1. A method of treating acute exacerbation of chronic obstructive pulmonary disease (COPD) in a subject in need thereof comprising administering to the subject a therapeutically effective amount of at least one natural killer T (NKT) cell agonist.2. The method of wherein the acute exacerbation of COPD is caused by a bacterial infection.3Streptococcus pneumoniae,Haemophilus influenzae.. The method of wherein the bacterial infection is due to or4. The method of wherein the NKT cell agonist is a alpha-galactosylceramide compound.5. The method of wherein the NKT cell agonist comprises a particulate entity comprising at least one alpha-galactosylceramide compound and at least one targeting agent that targets said to alpha-galactosylceramide compound to human BDCA3+ dendritic cells in vivo.6. The method of wherein the NKT cell agonist is an antibody7. The method of wherein the antibody is modified to reduce or inhibit the ability of the antibody to mediate antibody dependent cellular cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) functionality.8. The method of wherein the antibody has no Fc portion or has an Fc portion that does not bind FcyRI FcyRIII or Clq.9. The method of wherein the antibody has a Fc portion which is genetically or chemically altered to eliminate the Antibody dependent cell cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) functionality.10. The method of wherein the antibody comprises a heavy chain having an amino acid sequence set forth as SEQ ID NO: 1.11. The method of wherein the antibody ...

COMPOSITION CONTAINING ECTOINE OR HYDROXYECTOINE AS AN ACTIVE SUBSTANCE FOR PROMOTING THE REGENERATION OF INJURED BODY TISSUE

The invention relates to a composition containing as active agent ectoine, hydroxyectoine, glucosylglycerol and/or salts, esters or amides of these compounds for promoting the regeneration of injured body tissue. The invention has special significance for the treatment of chronic wounds or ulcers. 1. A method of promoting regeneration of injured body tissue in a patient in need thereof , comprising administering to the patient an effective amount of a composition containing as active agent ectoine , hydroxyectoine , glucosylglycerol and/or salts , esters or amides of these compounds.2. The method according to claim 1 , characterized in that the body tissue is skin or mucous membrane.3. The method according to claim 1 , characterized in that the injury of the body tissue is of traumatic nature.4. The method according to claim 1 , characterized in that the injury of the body tissue is an ulcer.5. The method according to claim 1 , characterized in that the injury of the body tissue is a chronic injury.6. The method according to claim 5 , characterized in that the chronic injury is a chronic wound or a chronic ulcer.7. The method according to claim 5 , characterized in that the injury of the body tissue is due to the diabetic foot syndrome.8. The method according to claim 1 , characterized in that the injury of the body tissue is due to a decubitus ulcer.9. The method according to claim 1 , characterized in that the injury of the body tissue is an anal fissure or hemorrhoids injury.10. The method according to claim 1 , characterized in that the glucosylglycerol is 2-O-α-glucosylglycerol or 2-O-β-glucosylglycerol.11. The method according to claim 10 , characterized in that the glucosylglycerol is 2-O-α-D-glucosylglycerol.12arnica montanaarnicacapsicumhypericum perforatumcardiospermum halicacabumhamamelis virginianacalendula officinalismelilotus officinalissymphytumechium vulgarecumin, angelica sinensisaloe veramatricaria recutitaallium cepaachillea ...

USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGS) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION AND CHEMICAL DAMAGE

The invention provides compositions and methods for radioprotection and chemoprevention using therapeutic and prophylactics methods of using (S,S)-SDG (R,R)-SDG, (S,R)-SDG (R,S)-SDG, SDG, SECO, EL, ED, analogs thereof, stereoisomers thereof and other related molecules. 189.-. (canceled)90. A method for treating asthma in a subject in need thereof , the method comprising: administering to the subject a therapeutically effective amount of secoisolariciresinol diglucoside (SDG).91. The method of claim 90 , wherein the SDG is (S claim 90 ,S)-SDG.92. The method of claim 90 , wherein the SDG is (R claim 90 ,R)-SDG.93. The method of claim 90 , wherein the SDG is synthetic SDG.94. The method of claim 90 , wherein the SDG is administered in a dietary composition.95. The method of claim 90 , wherein administering comprises orally administering.96. The method of claim 90 , wherein the SDG is in a concentration about 1 nanomolar (nM) to about 1 molar (M).97. The method of claim 96 , wherein the SDG concentration is about 25 μM to about 250 μM.98. The method of claim 90 , wherein the subject is a human subject. This application is a continuation of U.S. patent application Ser. No. 15/315,349, filed on Nov. 30, 2016, which is a National Phase Application of PCT International Application PCT/US15/33501, filed Jun. 1, 2015, claiming priority to U.S. Provisional Patent Applications 62/101,293, filed Jan. 8, 2015 and 62/005,330, filed May 30, 2014. Each of the above-identified applications is incorporated by reference herein in its entirety.This invention was made with government support under Grant Numbers CA133470, ES013508, AI081251, ES023720, CA180548 and CA016520 awarded by the National Institutes of Health. The government has certain rights in the invention.Provided herein are compositions and methods for radioprotection and radiation mitigation and for chemoprevention, such as from carcinogen-induced lung cancer and mesothelioma or from hypochlorite ions, using ...

COMPOSITIONS OF CRUDE ALGAL OIL

The present invention provides compositions for a crude algal oil and methods of making thereof. The compositions can be used to produce a highly pure omega-3 eicosapentaenoic acid (EPA) formulation. 1. A crude algal oil composition comprisingabout 30% to about 35% eicosapentaenoic acid (EPA),less than about 10% arachidonic acid (ARA.), andless than about 0.5% docosahexaenoic acid (PHA) by weight of total fatty acids.2. A crude algal oil composition comprisinga triacylglycerol fraction of at least about 2% by weight of total fatty acids,wherein about 7% of the eicosapentaenoic acid (EPA) of the crude algal oil is in the triacylglycerol fraction,wherein about 11% of the arachidonic acid (ARA) of the crude algal oil is in the triacylglycerol fraction, andwherein substantially no docosahexaenoic acid (DHA) is in the triacylglycerol fraction.3. A crude algal oil composition comprisinga monogalatosyldiacylglycerol (MGDG) fraction of at least about 5% by weight of total atty acids,wherein about 37% of the eicosapentaenoic acid (EPA) of the crude algal oil is in the MGDG fraction,wherein about 14% of the arachidonic acid (ARA) of the crude algal oil is in the MGDG fraction and,wherein substantially no docosahexaenoic acid (DHA) is in the MGDG fraction.4. The composition of claim 1 , wherein DHA is less than about 0.1%.5. The composition of claim 1 , wherein the composition is substantially free of DHA.6. The composition of claim 1 , wherein the EPA:ARA ratio ranges from about 5:1 to about 40:1.7. The composition of claim 1 , wherein the EPA:ARA ratio ranges from about 6:1 to about 30:1.8. The composition of claim 1 , wherein about 80% of the EPA in the crude algal oil is in polar lipids and about 20% of the EPA is in neutral lipids.9. The composition of claim 1 , wherein about 37% of the EPA in the crude algal oil is in monogalactosyldiacylglycerol lipids.10. The composition of claim 1 , wherein about 10% of the EPA in the crude algal oil is in free fatty acids claim 1 , ...

TLR4 agonists and compositions thereof and their use in the treatment of cancer

Disclosed is a TLR4 agonist alone or in combination with an anti-cancer agent and pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said composition or combination, including uses in cancer. 25-. (canceled)6. A combination kit comprising the composition as claimed in claim 1 , together with at least one pharmaceutically acceptable carrier.7. A pharmaceutical composition comprising the composition as claimed in claim 1 , together with at least one component chosen from: a pharmaceutically acceptable diluent claim 1 , a carrier claim 1 , and an excipient.911-. (canceled)12. A method of treating cancer in a human in need thereof comprising administering the composition as claimed in .13. A method of treating cancer in a human in need thereof comprising administering the pharmaceutical composition as claimed in .14. The method as claimed in claim 13 , wherein the anti-cancer agent and the TLR4 agonist claim 13 , CRX-601 claim 13 , are administered at the same time.15. The method as claimed in claim 13 , wherein the anti-cancer agent and the TLR4 agonist claim 13 , CRX-601 claim 13 , are administered sequentially claim 13 , in any order.16. The method as claimed in claim 13 , wherein the anti-cancer agent and the TLR4 agonist claim 13 , CRX-601 claim 13 , are administered via a systemic intravenous dose.17. The method as claimed in claim 13 , wherein the anti-cancer agent is administered intravenously and the TLR4 agonist claim 13 , CRX-601 claim 13 , is administered intratumorally.18. The method as claimed in claim 13 , wherein the anti-cancer agent is administered intratumorally and the TLR4 agonist claim 13 , CRX-601 claim 13 , is administered intravenously.19. The method as claimed in claim 13 , wherein the anti-cancer agent and the TLR4 agonist claim 13 , CRX-601 claim 13 , are both administered intratumorally.20. The method as claimed in claim 13 , wherein the cancer is a solid tumor.21. The method as claimed in ...

PROTECTIVE AGENT FOR KERATOCONJUNCTIVA OR SUPPRESSIVE AGENT FOR KERATOCONJUNCTIVAL DISORDER

An object of the present invention is to provide a protective agent for the keratoconjunctiva or a suppressive agent for a keratoconjunctival disorder having an excellent suppressive effect on a keratoconjunctival disorder. The invention relates to a protective agent for the keratoconjunctiva or a suppressive agent for a keratoconjunctival disorder containing glucosylglycerol as an active ingredient, use of glucosylglycerol for the manufacture of a pharmaceutical for protecting a keratoconjunctiva or suppressing a keratoconjunctival disorder and a method of protecting a keratoconjunctiva or suppressing a keratoconjunctival disorder comprising administering glucosylglycerol. 1. A protective agent for a keratoconjunctiva or a suppressive agent for a keratoconjunctival disorder comprising glucosylglycerol as an active ingredient.2. The protective agent for the keratoconjunctiva or the suppressive agent for a keratoconjunctival disorder according to claim 1 , wherein the agent is used for protecting the keratoconjunctiva against an endogenous disease of Sjogren's syndrome claim 1 , Stevens-Johnson syndrome claim 1 , or dry eye syndrome (dry eye) or an exogenous disease due to postsurgery claim 1 , a drug claim 1 , an injury claim 1 , or the wearing of a contact lens or suppressing the keratoconjunctival disorder due to said diseases.3. Use of glucosylglycerol for the manufacture of a pharmaceutical for protecting a keratoconjunctiva or suppressing a keratoconjunctival disorder.4. The use according to claim 3 , wherein the protection of the keratoconjunctiva or the suppression of the a keratoconjunctival disorder is protection of the keratoconjunctiva against an endogenous disease of Sjogren's syndrome claim 3 , Stevens-Johnson syndrome claim 3 , or dry eye syndrome (dry eye) or an exogenous disease due to postsurgery claim 3 , a drug claim 3 , an injury claim 3 , or the wearing of a contact lens or the suppression of the keratoconjunctival disorder due to said diseases. ...

PREPARATION FOR PREVENTING OR TREATING TYPE I DIABETES

The purpose of the present invention is to provide a preparation for preventing or treating type I diabetes, said preparation exerting an excellent effect of preventing or treating type I diabetes, and a method for preventing or treating type I diabetes. The onset and symptoms of type I diabetes can be very remarkably relieved by dosing a combination of: (A) at least one member selected from the group consisting of proinsulin, insulin, insulin A chain, insulin B chain, fragments thereof and variants thereof; with (B) α-GalCer. 1. A preparation for prevention or treatment of type I diabetes , comprising (A) at least one member selected from the group consisting of proinsulin , insulin , insulin A chain , insulin B chain , fragments thereof and variants thereof , and (B) α-galactosylceramide.2. The preparation according to claim 1 , wherein the component (A) is at least one member selected from the group consisting of proinsulin claim 1 , insulin B chain claim 1 , fragments thereof and variants thereof.3. The preparation according to claim 1 , wherein the component (B) is KRN7000.4. The preparation according to claim 1 , wherein the component (B) is contained in a liposome.5. The preparation according to claim 1 , wherein the component (A) and the component (B) are contained in a liposome.6. The preparation according to claim 1 , wherein the preparation is used for the prevention of type I diabetes.7. The preparation according to claim 1 , wherein the preparation is administered in the form of subcutaneous or intraperitoneal administration.8. A method for prevention or treatment of type I diabetes claim 1 , comprising 'wherein the preparation comprises (A) at least one member selected from the group consisting of proinsulin, insulin, insulin A chain, insulin B chain, fragments thereof and variants thereof, and (B) α-galactosylceramide.', 'administering a therapeutically or prophylactically effective amount of a preparation to a human in need of prevention or treatment ...

USE OF MANNURONIC DIACID COMPOSITION IN TREATMENT OF PARKINSON'S DISEASE

The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of Parkinson's disease. 2. The method of claim 1 , wherein in the mannuronic diacid oligosaccharide composition claim 1 , the total weight of mannuronic diacids wherein n=1-2 accounts for 10-50% of the total weight of the composition.3. The method of claim 1 , wherein in the mannuronic diacid oligosaccharide composition claim 1 , the ratio of the total weight of mannuronic diacids wherein n=1-3 to the total weight of mannuronic diacids wherein n=4-7 is between 1.0 and 3.5.4. The method of claim 1 , wherein in the mannuronic diacid oligosaccharide composition claim 1 , the total weight of mannuronic diacids with m+m′=1 or 2 is no less than 50% of the total weight of the composition.5. The method of claim 4 , wherein the total weight of mannuronic diacids with m+m′=1 is no less than 10% of the total weight of the composition.6. The method of claim 4 , wherein the total weight of mannuronic diacids with m+m′=2 is no less than 10% of the total weight of the composition.7. The method of claim 1 , wherein the total weight of mannuronic diacids wherein n=1-5 accounts for 80-95% of the total weight of the composition.8. The method of claim 1 , wherein the total weight of mannuronic diacids wherein n=1-3 accounts for 20-70% of the total weight of the composition.9. The method of claim 3 , wherein the ratio of the total weight of mannuronic diacids wherein n=1-3 to the total weight of mannuronic diacids wherein n=4-7 is between 1.0 and 3.0.10. The method of claim 1 , wherein the weight percentage content of mannuronic diacids with each of polymerization degrees in the composition is: disaccharide 5-25% claim 1 , trisaccharide 15-30% claim 1 , tetrasaccharide 15-28% claim 1 , pentasaccharide 5-25% claim 1 , hexasaccharide 2-20% claim 1 , heptsaccharide 2-20% claim 1 , octasaccharide 2-20% claim 1 , nonasaccharide 2-20% claim 1 , decasaccharide 2-20%.11. The method of ...

D-TAGATOSE-BASED COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ATHEROSCLEROSIS, METABOLIC SYNDROME, AND SYMPTOMS THEREOF

Pharmaceutical compositions including D-tagatose along with a stilbene or stilbenoid component, or a salt or derivative thereof. Methods of prophylaxis and therapy by administering to a mammal a pharmaceutically effective amount of D-tagatose, optionally in combination with a stilbene or stilbenoid component, or a salt or derivative thereof to prevent or treat atherosclerosis, the metabolic syndrome, obesity, or diabetes. 121-. (canceled)22. A composition comprising a pharmaceutically effective amount of a first pharmaceutically active drug which comprises D-tagatose , or a pharmaceutically acceptable salt , sugar alcohol , hydrate , solvate , ester , amide , or prodrug thereof , and a pharmaceutically effective amount of a second pharmaceutically active drug which comprises a stilbene or stilbenoid component or any pharmaceutically acceptable salt , alcohol , hydrate , ester , amide , polymorph , isomer , or prodrug or combination thereof , wherein the composition is capable of decreasing a level of a triglyceride , a low-density lipoprotein , or a cholesterol in a subject.23. The composition of claim 22 , wherein the second pharmaceutically active drug comprises a stilbene or stilbenoid component claim 22 , or any pharmaceutically acceptable salt thereof.24. The composition of claim 23 , wherein the stilbene or stilbenoid component comprises resveratrol or a resveratrol derivative claim 23 , or a combination thereof.25. The composition of claim 24 , wherein the resveratrol derivative comprises a resveratrol dimer.26. The composition of claim 25 , wherein the resveratrol dimer comprises resveratrol trans-dehydrodimer claim 25 , resveratrol (E)-dehydrodimer 11′-O-β-D-glucopyranoside claim 25 , resveratrol (E)-dehydrodimer 11-O-β-D-glucopyranoside and viniferins claim 25 , or an isomer thereof claim 25 , or a combination thereof.27. The composition of claim 22 , wherein the composition is effective to decrease a total serum triglyceride level in a patient's blood by ...

ABX196 FOR USE IN THE TREATMENT OF BLADDER CANCER

The compound ABX196 and pharmaceutical compositions including ABX196 are used in the treatment of bladder cancer. 2. The method according to claim 1 , wherein the bladder cancer is selected among the group consisting of: bladder transitional cell carcinoma claim 1 , bladder squamous cell carcinoma claim 1 , and bladder adenocarcinoma.3. The method according to claim 2 , wherein the bladder cancer is the bladder transitional cell carcinoma.4. The method according to claim 1 , wherein the bladder cancer is a superficial or an invasive cancer.5. The method according to claim 1 , wherein the compound ABX196 is administered intravesically or intravenously.6. The method according to claim 1 , wherein said method of treatment of bladder cancer further comprises surgery and/or radiation therapy.7. The method according to claim 1 , wherein volume of a bladder tumor is decreased after treatment with the compound ABX196 compared to the tumor volume before treatment. The present invention concerns the compound ABX196 and pharmaceutical compositions comprising it, for use in the treatment of bladder cancer.Cancer is a leading cause of mortality, despite years of research and treatment advances. In particular, bladder cancer is one of the most common cancers among men. In 2014, there were an estimated 696,440 people living with bladder cancer in the United-States.The bladder is a hollow organ in the lower part of the abdomen that stores urine until it is passed out of the body. In bladder cancer, malignant (tumoral) cells form in the tissues of the bladder. Signs and symptoms of bladder cancer include blood in the urine (hematuria), pain during urination, frequent urination and lower back pain. It is known that smoking and frequent bladder infections can affect the risk of bladder cancer.Diagnosis is typically made by cystoscopy with tissue biopsies.The most common type of bladder cancer is transitional cell carcinoma which represents 90% of the bladder cancers and affects ...

ACTIVATION OF iNKT CELLS

The present invention relates to particulate entity, such as a nanoparticle or conjugate, for use in particular as adjuvant in vaccine or immunotherapy. More specifically, the invention relates to a particulate entity comprising: iv. an iNKT cell agonist such as α Gal Car compound, and, v. one or more antigenic determinant(s) such as a tumour antigen(s) or pathogen-derived antigen(s), vi. a targeting agent that targets in vivo said iNKT cell agonist to dendritic cells, such as human BDCA3-dendritic cells. 1. A method for treating a tumor in a subject in need thereof , said method comprising administering a therapeutically efficient amount of a nanoparticle comprising:i. a core containing polymers,ii. a coating,iii. an α-GalCer compound,iv. one or more antigenic determinant(s) specific for said tumor cell, andv. a targeting agent comprising an antibody or its antigen-binding fragment that specifically binds to a cell surface marker specific of human BDCA-3+ dendritic cells,wherein said nanoparticle does not comprise a CD1d molecule, and wherein said targeting agent is covalently linked to a surface of the coating.2. The method of claim 1 , wherein said nanoparticle has a size between 10 to 2000 nm diameter.3. The method of claim 1 , wherein said core comprises poly(lactic acid) claim 1 , poly(glycolic acid) claim 1 , or their co-polymers.4. The method of claim 1 , wherein said α-GalCer compound is α-galactosylceramide or its functional derivatives.5. The method of claim 1 , wherein said α-GalCer compound is α-galactosylceramide or its functional derivatives.6. The method of claim 1 , wherein said α-GalCer compound and said one or more antigenic determinant(s) are encapsulated within the nanoparticle.7. The method of claim 1 , wherein said α-GalCer compound and said one or more antigenic determinant(s) are physically coupled to the nanoparticles.8. The method of claim 1 , wherein said cell surface marker specific human BDCA3+ is CLEC9A. The present invention relates ...

USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION AND CHEMICAL DAMAGE

The invention provides compositions and methods for radioprotection and chemoprevention using therapeutic and prophylactics methods of using (S,S)-SDG (R,R)-SDG, (S,R)-SDG (R,S)-SDG, SDG, SECO, EL, ED, analogs thereof, stereoisomers thereof and other related molecules. 1. A method for protecting a biomolecule , a cell , or a tissue from radiation damage in a subject in need thereof , the method comprising: administering to said subject an effective amount of at least one bioactive ingredient , wherein said bioactive ingredient comprises secoisolaricirecinol digluco side (SDG) , secoisolariciresinol (SECO) , enterodiol (ED) , enterolactone (EL) , analogs thereof , stereoisomers thereof , or a combination thereof.2. (canceled)3. (canceled)4. The method of claim 1 , wherein the subject has been or will be exposed to radiation as part of a therapeutic procedure or as part of a diagnostic procedure.5. The method of claim 4 , wherein the subject is a cancer patient who has or will receive radiotherapy.6. (canceled)7. (canceled)8. The method of claim 4 , wherein the diagnostic procedure is a dental or bone X-ray or a PET or CT scan.9. (canceled)10. The method of claim 1 , wherein the subject has been accidentally exposed to radiation.11. The method of claim 1 , wherein the subject has been or will be exposed to radiation as part of their occupation.12. (canceled)13. The method of claim 1 , wherein the subject has been exposed to radon or to radiation as a result of terrorism.14. (canceled)15. A method for protecting a biomolecule claim 1 , a cell claim 1 , or a tissue from carcinogen-induced damage claim 1 , malignant transformation and cancer development in a subject in need thereof claim 1 , the method comprising: administering to said subject an effective amount of at least one bioactive ingredient claim 1 , wherein said bioactive ingredient comprises secoisolaricirecinol diglucoside (SDG) claim 1 , secoisolariciresinol (SECO) claim 1 , enterodiol (ED) claim 1 , ...

GLYCOLIPID CONTAINING COMPOSITIONS FOR USE IN THE TREATMENT OF TUMOURS

The invention relates to pharmaceutical compositions comprising α-Gal BOEL for use in treating patients with tumors. The invention also relates to methods of treating tumours using said compositions. The invention discloses that following intratumoral injection of α-Gal BOEL, binding of the natural anti-Gal antibody to de novo expressed tumoural α-Gal epitopes induces inflammation resulting in an anti-Gal antibody mediated opsonization of tumour cells and their uptake by antigen presenting cells. These antigen presenting cells migrate to draining lymph nodes and activate tumour specific T cells thereby converting the treated tumour lesions into in situ autologous tumour vaccines. This therapy can be applied to patients with multiple lesions and in neo-adjuvant therapy to patients before tumour resection. In addition to the regression and/or destruction of the treated tumour, such a vaccine will help in the immune mediated destruction of micrometastases that are not detectable during the removal of the treated tumour. The invention further teaches the enhancement of anti-tumour α-Gal BOEL treatment by the use of antibodies that inhibit the activity of immunological checkpoints molecules.

IMMUNE-TOLERANCE INDUCER

The purpose of the present invention is to create an immune tolerance-inducing agent used in therapy in which donor hematopoietic cells are transplanted into a recipient in order to induce immune tolerance in the recipient with respect to donor cells, tissue, or organs. By using an alpha-galactosylceramide-containing liposome in combination with a costimulatory-pathway-blocking substance, hematopoietic chimerism can be induced in the recipient by transplantation of donor hematopoietic cells, making it possible to induce immune tolerance in the recipient with respect to donor cells, tissue, or organs. 1. An immune tolerance-inducing agent , comprising a liposome comprising α-galactosylceramide and a substance inhibiting costimulatory pathway.2. The immune tolerance-inducing agent according to claim 1 , wherein the costimulatory pathway is CD40/CD40L costimulatory pathway.3. The immune tolerance-inducing agent according to claim 1 , wherein the substance inhibiting costimulatory pathway is an anti-CD40 antibody or an anti-CD40L antibody.46-. (canceled)7. The immune tolerance-inducing agent according to claim 1 , wherein the liposome comprising α-galactosylceramide and the substance inhibiting costimulatory pathway are contained in one preparation.8. The immune tolerance-inducing agent according to claim 1 , which is of a two-agent form comprising a preparation comprising the liposome comprising α-galactosylceramide and a preparation comprising the substance inhibiting costimulatory pathway.9. A method for inducing immune tolerance in a recipient with respect to donor cells claim 1 , tissue claim 1 , or organ claim 1 , comprising administering liposome comprising α-galactosylceramide and a substance inhibiting costimulatory pathway to the recipient into which donor hematopoietic cells were transplanted or the recipient into which donor hematopoietic cells are to be transplanted.10. (canceled)11. A hematopoietic cell chimeria-inducing agent claim 1 , comprising liposome ...

USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION-INDUCED CARDIOVASCULAR DYSFUNCTION

The invention relates to the use of secoisolariciresinol diglucoside (SDG), obtained from natural sources, such as flaxseed, or generated synthetically (synthetic SDG is also referred to herein as LGM2605), other active components in flaxseed, secoisolariciresinol (SECO), enterodiol (ED), and enterolactone (EL), as well as stereoisomers of the foregoing, metabolites of the foregoing, degradants of the foregoing, and analogs of the foregoing, to treat and protect cardiac and vascular tissues, for example, treating ionizing radiation-associated vascular injury and vasculopathy and protecting vascular tissue against ionizing radiation exposure. 1. A method for treating or preventing radiation-associated vascular injury in a subject in need thereof , the method comprising: administering to said subject an effective amount of secoisolaricirecinol diglucoside (SDG) , an analog thereof , a stereoisomer thereof , or a combination thereof , thereby treating said radiation-induced vascular damage in said subject.2. The method of claim 1 , wherein said SDG is (S claim 1 ,S)-SDG.3. The method of claim 1 , wherein said SDG is (R claim 1 ,R)-SDG.4. The method of claim 1 , wherein said SDG is a synthetic SDG.5. The method of claim 1 , wherein said SDG is an SDG analog.6. The method of claim 1 , wherein said step of administering is performed orally.7. The method of claim 1 , wherein said SDG is administered at a concentration from about 1 nanomolar (nM) to about 1 molar (M).8. The method of claim 1 , wherein the subject is a human subject.9. The method of claim 1 , wherein said radiation is proton radiation.10. The method of claim 1 , wherein said radiation is associated with a medical treatment.11. The method of claims 1 , wherein the subject has been or will be exposed to radiation as part of a therapeutic procedure.12. The method of claim 1 , wherein the subject is a cancer patient and said radiation is associated with a radiation cancer therapy.13. The method of claim 12 , ...

BEAUTYBERRY TOTAL GLYCOSIDES EXTRACT AND PREPARATION METHOD AND USE THEREOF

Disclosed is a composition comprising an beautyberry total glycosides extract, and a method of preparation thereof, and the use of the composition thereof in preparing drugs for treating neurodegenerative diseases or skin diseases. The extract thereof is prepared from the leaves of H. T. Chang or Rolfe, and contains 18% to 45% verbascoside and 15% to 40% Arenarioside. 110.-. (canceled)11Callicarpa cathayanaCallicarpa formosana. A beautyberry total glycosides extract , containing 18% to 45% verbascoside and 15% to 40% Arenarioside based on weight , wherein the extract is prepared from leaves of H. T. Chang or Rolfe.12. The beautyberry total glycosides extract according to claim 11 , containing 28% to 45% verbascoside based on weight.13. The beautyberry total glycosides extract according to claim 11 , containing 24% to 40% Arenarioside based on weight.14. The beautyberry total glycosides extract according to produced by:{'i': Callicarpa cathayana', 'Callicarpa formosana, '(1) pulverizing leaves of H. T. Chang or Rolfe, and extracting with a solvent 1 to 3 times, where the solvent is water, alcohol, or a mixture of water and alcohol;'}(2) combining extract liquors from each extraction, concentrating under reduced pressure to remove the organic solvent in step (1); adding therein water in an amount of 0.5 to 2 times the volume, standing overnight, centrifuging or filtering to obtain supernatant; and(3a) passing the supernatant through a chromatographic column packed with a resin filler, washing with water and/or a dilute alcohol aqueous solution to remove impurities, then eluting with an alcohol aqueous solution at a higher concentration, collecting eluent, concentrating under reduced pressure, and drying, so as to obtain the beautyberry total glycosides extract; or(3b) extracting the supernatant with an organic solvent, concentrating the organic phase under reduced pressure, and drying, so as to obtain the beautyberry total glycosides extract.15. The beautyberry total ...

EPHEDRA ALATA EXTRACTS AND METHODS OF USE THEREOF

Ephedra alata aqueous extracts, powders and constituents thereof are encompassed herein, as are compositions thereof. Methods of using same for treating inflammatory diseases, autoimmune diseases, cancers, viral diseases, and neurodegenerative diseases are also envisioned. 1. An aqueous extract or powder or a constituent thereof generated from Ephedra alata.2. The aqueous extract or powder or constituent thereof of claim 1 , wherein the aqueous extract or powder or constituent thereof comprises at least one of p-coumaric claim 1 , ephedralone or derivatives thereof claim 1 , furanofuran lignan claim 1 , syringaresinol claim 1 , nilocitin and digallooylglucose.3. The aqueous extract or powder or constituent thereof of claim 1 , wherein the aqueous extract or powder or constituent thereof comprises at least one of alkaloidal claim 1 , lignan and phenolic constituents of Ephedra alata.4. A composition comprising the aqueous extract or powder or constituent thereof of and a pharmaceutically acceptable excipient or carrier.5. A method for making the aqueous extract of claim 1 , the method comprising:processing an Ephedra alata plant or specific parts thereof in an aqueous solution to generate a supernatant comprising solubilized agents and insoluble material; andremoving the insoluble material from the supernatant, thereby generating the Ephedra alata aqueous extract.6. The method of claim 5 , wherein the processing comprises boiling fresh or dried Ephedra alata plant or specific parts thereof in water.7. The method according to any one of - claim 5 , wherein the removing comprises gravity separation claim 5 , centrifugation claim 5 , and/or sieving through a filter.8. The method according to any one of - claim 5 , wherein the Ephedra alata plant or specific parts thereof are fresh or dehydrated.9. The method according to any one of - claim 5 , wherein the specific parts are leaves and small branches or leaves of the Ephedra alata plant.10. The method according to any ...

METHODS AND COMPOSITIONS FOR TREATMENT OF METABOLIC DISORDERS

The present invention relates to the discovery that increases in invariant NKT cell (iNKT) number and/or activity can reduce the incidence or severity of metabolic disorders such as obesity and diabetes. The invention accordingly features methods, kits, and compositions for the treatment of such metabolic disorders by administration of a composition capable of increasing iNKT activity. 1. A method of treating a subject suffering from a metabolic disorder , said method comprising administering to said subject a sufficient amount of a composition that increases invariant NKT (iNKT) cell activity.2. The method of claim 1 , wherein said composition comprises a glycolipid; an antibody or an antigen-binding fragment thereof; or an iNKT.3. The method of claim 2 , wherein said glycolipid is a bacterial glycolipid capable of activating iNKT.4. The method of claim 2 , wherein said glycolipid is α-galactosylceramide or an analog thereof.5. The method of claim 2 , wherein said antibody or antigen-binding fragment thereof specifically binds to an iNKT and increases activity of said iNKT.6. The method of claim 5 , wherein said antibody or antigen-binding fragment thereof binds to the CDR3 loop or the α-β junction of said iNKT.7. The method of claim 2 , wherein said iNKT is an autologous iNKT.8. The method of claim 1 , wherein said composition further comprises a pharmaceutically acceptable carrier or wherein said composition is administered intravenously claim 1 , intramuscularly claim 1 , orally claim 1 , by inhalation claim 1 , parenterally claim 1 , intraperitoneally claim 1 , intraarterially claim 1 , transdermally claim 1 , sublingually claim 1 , nasally claim 1 , transbuccally claim 1 , liposomally claim 1 , adiposally claim 1 , ophthalmically claim 1 , intraocularly claim 1 , subcutaneously claim 1 , intrathecally claim 1 , topically claim 1 , or locally.9. (canceled)10. A method for treating a subject suffering from a metabolic disorder claim 1 , said method comprising ...

COMPOSITION AND METHOD OF USE FOR COMBINATIONS OF ANTI-VIRAL PROTEASE, POLYMERASE INHIBITORS AND NATURAL BIOACTIVE COMPOUNDS IN THE TREATMENT OF HEPATITIS C INFECTION

A composition and associated method for treating a hepatitis C virus (HCV) infection in a subject who is human being. The composition includes: an anti-viral agent and/or a protease inhibitor; a polymerase inhibitor; one or more viral entry inhibitors; and one or more anti-fibrotic agents and/or anti-hemolytic agents including one or more Polyphenols and/or one or more Thiols. The composition may also include one or more sulfated oligosaccharide or non-anticoagulant glycosaminoglycans (GAGs). The method administers, to the subject, a therapeutic dose of the composition to treat the subject for the HCV infection. 1. A composition , comprising:an anti-viral agent and/or a protease inhibitor;a polymerase inhibitor;one or more viral entry inhibitors; andone or more anti-fibrotic agents and/or anti-hemolytic agents comprising one or more Polyphenols and/or one or more Thiols.2. The composition of claim 1 , further comprising:one or more non-anticoagulant glycosaminoglycans (GAGs).3. The composition of claim 2 , wherein the one or more non-anticoagulant glycosaminoglycans comprise one or more sulfated oligosaccharide non-anticoagulant glycosaminoglycans.4. The composition of claim 1 , wherein the anti-viral agent and/or a protease inhibitor comprises the anti-viral agent.5. The composition of claim 4 , wherein the anti-viral agent comprises ribavirin.6. The composition of claim 4 , wherein the anti-viral agent comprises taribavirin.7. The composition of claim 1 , wherein the anti-viral agent and/or a protease inhibitor comprises the protease inhibitor.8. The composition of claim 7 , wherein the protease inhibitor is boceprevir claim 7 , telaprevir claim 7 , or simeprevir.9. The composition of claim 1 , wherein the polymerase inhibitor is Sofosbuvir.10. The composition of claim 1 , wherein the one or more viral entry inhibitors comprise epigallocatechin gallate (EGCG) and/or sulfated glycosaminoglycans.11. The composition of claim 1 , wherein the one or more Polyphenols ...

PROTECTIVE AGENT FOR KERATOCONJUNCTIVA OR SUPPRESSIVE AGENT FOR KERATOCONJUNCTIVAL DISORDER

An object of the present invention is to provide a protective agent for the keratoconjunctiva or a suppressive agent for a keratoconjunctival disorder having an excellent suppressive effect on a keratoconjunctival disorder. The invention relates to a protective agent for the keratoconjunctiva or a suppressive agent for a keratoconjunctival disorder containing glucosylglycerol as an active ingredient, use of glucosylglycerol for the manufacture of a pharmaceutical for protecting a keratoconjunctiva or suppressing a keratoconjunctival disorder and a method of protecting a keratoconjunctiva or suppressing a keratoconjunctival disorder comprising administering glucosylglycerol. 1. A method of protecting a keratoconjunctiva or suppressing a keratoconjunctival disorder comprising administering glucosylglycerol.2. The method according to for protecting the keratoconjunctiva against an endogenous disease of Sjogren's syndrome claim 1 , Stevens-Johnson syndrome claim 1 , or dry eye syndrome (dry eye) or an exogenous disease due to postsurgery claim 1 , a drug claim 1 , an injury claim 1 , or the wearing of a contact lens or suppressing the keratoconjunctival disorder due to said diseases.3. The method of wherein the glucosylglycerol is 1-α-glyceryl glucoside claim 1 , 2-α-glyceryl glucoside claim 1 , 1-β-glyceryl glucoside claim 1 , 2-β-glyceryl glucoside or a mixture thereof.4. The method of comprising: administrating a pharmaceutical agent containing the glucosylglycerol as an active ingredient in an effective amount for protecting keratoconjunctiva or suppressing a keratoconjunctival disorder; and an ophthalmically acceptable carrier.5. The method according to for protecting the keratoconjunctiva against an endogenous disease of Sjogren's syndrome claim 4 , Stevens-Johnson syndrome claim 4 , or dry eye syndrome (dry eye) or an exogenous disease due to postsurgery claim 4 , a drug claim 4 , an injury claim 4 , or the wearing of a contact lens or suppressing the ...

COMPOSITIONS AND METHODS FOR TREATING LUNG DISEASES

The invention relates compositions and methods for treating pathological lung conditions using whole-grain flaxseed or flaxseed lignans. Specifically, the invention relates to the dietary use of flaxseed lignans. 1. A method for therapeutically treating a radiation-induced lung disease in a subject , the method comprising: administering to said subject a therapeutically effective amount of flaxseed , its bioactive ingredient , or a metabolite thereof , thereby treating said radiation-induced lung disease in said subject.2. The method of claim 1 , wherein said flaxseed is a whole grain flaxseed.3. The method of claim 1 , wherein said metabolite is a flaxseed lignan metabolite.4. The method of claim 1 , wherein said bioactive ingredient is a flaxseed lignan complex (FLC) that comprises a plant lignan precursor claim 1 , a seciosolariciresinol diglucoside (SDG) claim 1 , a mammalian lignan enterodiol claim 1 , an enterolactone claim 1 , or a combination thereof.5. The method of claim 1 , wherein administering comprises increasing dietary intake of flaxseed claim 1 , its bioactive ingredient claim 1 , or a metabolite thereof.6. The method of claim 1 , wherein said radiation-induced lung disease is a lung inflammation.7. The method of claim 1 , wherein said radiation-induced lung disease is a pulmonary fibrosis.8. The method of claim 1 , wherein said radiation-induced lung disease is a lung injury.9. The method of claim 1 , wherein said lung injury is the result of acute or oxidative lung injury.10. The method of claim 1 , wherein said subject is an individual exposed to inhaled radioisotope or incidental radiation.11. A composition for therapeutically treating a radiation-induced lung disease in a subject claim 1 , the composition comprising a therapeutically effective amount of flaxseed claim 1 , its bioactive ingredient claim 1 , or a metabolite thereof.12. The composition of claim 11 , wherein said flaxseed is a whole grain flaxseed.13. The composition of claim 11 , ...

ACTIVATION OF iNKT CELLS

The present invention relates to particulate entity, such as a nanoparticle or conjugate, for use in particular as adjuvant in vaccine or immunotherapy. More specifically, the invention relates to a particulate entity comprising: iv. an iNKT cell agonist such as α Gal Car compound, and, v. one or more antigenic determinant(s) such as a tumour antigen(s) or pathogen-derived antigen(s), vi. a targeting agent that targets in vivo said iNKT cell agonist to dendritic cells, such as human BDCA3+ dendritic cells. 1. A particulate entity comprising:i. an invariant Natural Killer T (iNKT) cell agonist,ii. optionally, one or more antigenic determinant(s), and,iii. a targeting agent that targets in vivo said iNKT cell agonist, to dendritic cells.2. The particulate entity of claim 1 , wherein said targeting agent targets said iNKT cell agonist to human BDCA3+ cells.3. The particulate entity of claim 1 , wherein said particulate entity is a nanoparticle having a size between 10 to 2000 nm diameter.4. The particulate entity of claim 3 , which is a nanoparticle comprising a core containing polymers and a coating claim 3 , wherein said targeting agent is covalently linked to the surface of the coating.5. The particulate entity of claim 4 , wherein said core comprises poly(lactic acid) claim 4 , poly(glycolic acid) claim 4 , or their co-polymers.6. The particulate entity of claim 1 , wherein said particulate entity is a conjugate consisting of said iNKT agonist covalently linked to the targeting agent claim 1 , optionally via a linker.7. The particulate entity of claim 1 , wherein said iNKT agonist is α-galactosylceramide or its functional derivatives.8. The particulate entity of claim 1 , wherein said targeting agent comprises a binding molecule that specifically binds to a cell surface marker of human BDCA-3+ dendritic cells.9. The particulate entity of claim 8 , wherein said cell surface marker of BDCA-3+ dendritic cells is selected from the group consisting of XCR-1 and CLEC9A. ...

METHOD FOR TREATMENT OF DISEASE WITH PURE PORCINE MONOSIALOGANGLIOSIDE GM1

A process for preparing pure monosialoganglioside GM1 in the form of its sodium salt. There is provided a process for the isolation and purification of monosialoganglioside GM1 comprising (a) separation of GM1 from a lipidic mixture containing the monosialoganglioside GM1 as the main ganglioside component by ion exchange column-chromatography using an eluent comprising potassium or caesium ions, (b) recovery of the solute from the eluted solution, (c) diafiltration of an aqueous solution of the recovered solute, and (d) second diafiltration after the addition of 1 M NaCl, and recovering GM1. The purity level of GM1 obtained is higher than 99.0%. 118-. (canceled)191. A pharmaceutical composition comprising a monosialoganglioside GM of porcine origin containing less than 0.1% Fucosyl-GM1 , produced according to a process for the purification of monosialoganglioside GM1 comprising separating monosialoganglioside GM1 from Fucosyl-GM1 in a lipidic mixture containing the monosialoganglioside GM1 as the main ganglioside component , by ion exchange column-chromatography using an eluent comprising potassium or caesium ions.20. The pharmaceutical composition according to claim 19 , further comprising a pharmaceutically acceptable carrier.21. The pharmaceutical composition according to claim 19 , wherein said porcine monosialoganglioside GM1 is at least 99.0% pure.22. The pharmaceutical composition according to claim 19 , wherein the lipidic mixture containing the monosialoganglioside GM1 as the main ganglioside component has been obtained by acid hydrolysis or enzymatic hydrolysis of a lipid extract containing at least 30% of gangliosides.23Arthrobacter ureafaciensVibrio cholerae. The pharmaceutical composition according to claim 19 , wherein the lipidic mixture containing the monosialoganglioside GM1 as the main ganglioside component has been obtained by enzymatic hydrolysis of a lipid extract with an strain S sialidase or sialidase.24. The pharmaceutical composition ...

Sterically Stabilized Carrier for Aerosol Therapeutics, Compositions and Methods for Treating the Respiratory Tract of a Mammal

The application disclosure provides a sterically stabilized liposome carrier encapsulating a selected drug for the aerosol delivery of the drug effectual in the treatment of a mammal, a composition containing the sterically stabilized liposome carrier and the selected drug effective for the treatment of airway hypersensitivity and inflammation such as of the lungs of a mammal as an aerosol, and a method of treatment using the composition. The composition disclosed herein provides effective treatment for the longer of a period of time at least twice as long as the selected drug alone or up to at least one week. 125-. (canceled)26. A method for treating lung inflammation or airway hyperreactivity , comprising:administering to a subject in need thereof an aerosol formulation comprising a drug in an amount that is therapeutically effective for treating lung inflammation or airway hyperreactivity,wherein the drug is encapsulated in a sterically stabilized liposome carrier comprising a phosphatidylcholine (PC), a phosphatidylglycerol (PG), and a poly (ethylene glycol) di stearoylphosphatidyl ethanolamine (PEG-DSPE), andwherein the PC comprises synthetic palmitoyloleoyl-PG (POPC) or synthetic palmitoyloleoyl-PG (POPG).27. The method of claim 26 , wherein the sterically stabilized liposome carrier is free of cholesterol.28. The method of claim 26 , wherein the sterically stabilized liposome carrier comprises from about 0.1 to about 20 mole percent of cholesterol.29. The method of claim 26 , wherein the sterically stabilized liposome carrier comprises from about 20 to about 30 mole percent of the PG.30. The method of claim 26 , wherein the sterically stabilized liposome carrier comprises from about 1 to about 5 mole percent of the PEG-DSPE.31. The method of claim 26 , wherein the aerosol formulation has a particle size of more than 0.2 micrometer and up to 5 micrometers.32. The method of claim 26 , wherein the aerosol formulation comprises from about 1 to about 33 mole ...

Composition for preventing or treating oral disease comprising Echinacoside

본 발명은 에키나코사이드 또는 이의 약학적으로 허용 가능한 염을 포함하는 구강 질환의 예방, 치료 또는 개선용 조성물에 관한 것이다. 본 발명의 구강 질환 예방, 치료 또는 개선용 조성물은 샐리버리 뮤신 생성율을 증가시킬 수 있고, 항균 물질의 과도한 사용으로 인해 유발될 수 있는 저항성 또는 내성에 대한 염려가 없이 안전하게 사용할 수 있다. The present invention relates to a composition for preventing, treating or ameliorating an oral disease comprising echinacoside or a pharmaceutically acceptable salt thereof. The composition for preventing, treating or improving oral diseases according to the present invention can increase the production rate of salivary mucin and can be safely used without fear of resistance or tolerance that can be caused by excessive use of the antimicrobial substance.

Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal

This invention comprises a sterically stabilized liposome carrier encapsulating a selected drug for the aerosol delivery of the drug effectual in the treatment of the lungs of a mammal, a composition containing the sterically stabilized liposome carrier and the selected drug effective for the treatment of the lungs of a mammal for asthma and inflammation of the lungs of the mammal as an aerosol and a method of, treatment using the composition. The composition provides effective treatment for the longer of a period of time at least twice as long as the selected drug alone or up to at least one week.

Application of acteoside to preparation of antidepressant drugs

本发明涉及一种类叶升麻苷在制备抗抑郁药物中的用途，通过实验表明：本发明所述的类叶升麻苷在预防和治疗抑郁症的药物中具有较高的活性，从而能够将类叶升麻苷作为抗抑郁制药或相关先导化合物而用于制药生产，是一种安全、高效、稳定、价廉的抗抑郁的药物，具有很好的开发价值。

Composition for preventing or treating oral disease comprising Echinacoside

본 발명은 에키나코사이드 또는 이의 약학적으로 허용 가능한 염을 포함하는 구강 질환의 예방, 치료 또는 개선용 조성물에 관한 것이다. 본 발명의 구강 질환 예방, 치료 또는 개선용 조성물은 샐리버리 뮤신 생성율을 증가시킬 수 있고, 항균 물질의 과도한 사용으로 인해 유발될 수 있는 저항성 또는 내성에 대한 염려가 없이 안전하게 사용할 수 있다.

Pharmaceutical composition for treating central nervous system diseases and preparation method and application thereof

本发明公开了一种治疗中枢神经系统疾病的药物组合物，该药物组合物是由以下重量比组成：红景天苷5～60重量份，红芪多糖1～30重量份。本发明还提供了该药物组合物的制备方法。本发明还提供了该药物组合物的制备方法和具体用途。本发明药物组合物经药效实验证明可通过降低脑组织中的氧化产物和提高脑内抗氧化酶活性明显改善D‑半乳糖致痴呆小鼠模型的学习记忆能力，并能明显改善血管性痴呆大鼠的认知功能。同时，本发明药物配伍后具有不同程度的降血脂作用。

Composition for preventing, treating, or improving prostate cancer comprising Acer pseudosieboldianum (Pax) Komarov extract or fraction thereof

본 발명은 당단풍나무 추출물 또는 이의 분획물을 유효성분으로 포함하는, 전립선암의 예방, 치료, 또는 개선용 조성물에 관한 것으로서, 본 발명에 따른 당단풍나무 추출물, 이의 분획물, 또는 이로부터 분리한 화합물은 뛰어난 항산화, 항염증 효과를 가지고, 전립선암 세포에 대해 항증식 활성 및 세포사멸 촉진 활성을 나타내며, GSTP1 유전자의 DNA 메틸화를 억제함으로써 전립선암의 예방에 우수한 효과를 나타낸다. 이에, 본 발명의 당단풍나무 추출물, 이의 분획물, 또는 이로부터 분리한 화합물은 전립선암의 예방, 치료, 또는 개선용 조성물의 유효성분으로 유용하게 이용될 수 있을 것으로 기대된다. The present invention relates to a composition for the prevention, treatment, or improvement of prostate cancer, comprising an extract or a fraction thereof as an active ingredient, wherein the extract, a fraction thereof, or a compound isolated therefrom has an excellent It has antioxidant and anti-inflammatory effects, exhibits antiproliferative activity and apoptosis promoting activity against prostate cancer cells, and exhibits excellent effects in preventing prostate cancer by inhibiting DNA methylation of the GSTP1 gene. Accordingly, it is expected that the sugar maple extract, a fraction thereof, or a compound isolated therefrom of the present invention can be usefully used as an active ingredient in a composition for preventing, treating, or improving prostate cancer.

Improved pharmaceutical dry powder compositions for inhalation

A spray dried powder for use in dry inhalers, comprising particles (A) comprising active material, said particles being at least partially coated (C1, C2) with an active material so that the flowing and dispersing properties of the powder are enhanced.

A kind of preparation method for the PEGylated nano liposomes for embedding rhodioside

本发明提出了一种包埋红景天苷的PEG化纳米脂质体的制备方法。该方法将胆固醇、大豆卵磷脂、1,2‑二硬脂酰‑SN‑甘油‑3‑磷酰乙醇胺‑N‑马来酰亚胺‑聚乙二醇2000（DSPE‑PEG2000）和红景天苷溶于无水乙醇中，通过减压蒸发形成脂质薄膜；加入磷酸盐缓冲液充分水化，通过振荡、超声分散得到悬浮液；再通过挤压形成PEG化红景天苷纳米脂质体胶体溶液。本发明中PEG化红景天苷纳米脂质体的平均粒径小于100 nm，Zeta电位为‑33.4 mV，红景天苷的包封率为50‑60%。一般的脂质体脂溶性较强，能够开启免疫应答被巨噬细胞快速清除。本发明制备了红景天苷PEG化纳米脂质体，可克服红景天苷纳米脂质体因脂溶性强而被快速清除的问题，延长了红景天苷在体内有效的血药浓度时间，提高了生物利用度。

Application of cistanche tubulosa phenylethanoid glycosides in preparing anti-melanoma medicine

本发明属于医药领域，具体公开了管花肉苁蓉苯乙醇苷在制备抗黑色素瘤药物中的应用。所述管花肉苁蓉苯乙醇苷的主要成分为松果菊苷、毛蕊花糖苷和异麦角兹苷。实验表明，管花肉苁蓉苯乙醇苷在体外对黑色素瘤细胞的抑制率达到了90%以上，对体内的肿瘤生长抑制率达到了50%以上，黑色素瘤小鼠生存率从8%提高到40%，具有良好的抗黑色素瘤作用。

Method for treatment of lupus nephritis

It has been found that by administering secoisolariciresinol [2,3-bis(3-methyl-4-hydroxybenzyl)butane-1,4-diol] from flaxseed in substantially pure form to a human or non-human animal, lupus nephritis can be controlled. The secoisolariciresinol (Seco) may be used per se or in the form of secoisolariciresinol diglucoside (SDG). Both compounds may be extracted from flaxseed and the SDG converts to Seco in the gut of a human or animal.

Use of cholesterol derivatives for modulating sphingolipid-cholesterol microdomains

The invention relates to the use of gangliosides and other substances for producing an agent for modulating sphingolipid-cholesterol microdomains.

Allergy-protective formula food

The invention concerns the use of gangliosides containing N-acetyl neuraminic acid for allergy protection in humans and animals, especially premature and suckling infants and small children. According to the invention, an allergy-protective formula food containing these gangliosides is also produced.

Composition and a process thereof

The present invention relates to a novel herbal composition for improving exercise physiology factors comprising saponins and sugar derivatives optionally along with pharmaceutically acceptable excipients. It also relates to the process of preparing the composition for improving exercise physiology factors comprising the steps of flaking, defatting, solvent extraction of seeds of trigonella species followed by concentration of the extract to obtain a saponin and sugar derivative. It also relates to the use of the composition for improving exercise physiology factors comprising, enhanced anabolic activity, enhanced muscle building, enhance creatine delivery and reuptake, an increase in testosterone levels and an enhanced immunity.

Method for preparing sodium monosialic ganglioside and neuroprotective agent based on it

FIELD: pharmacology. SUBSTANCE: pig brain extract is prepared using a mixture of trichloromethane, methyl alcohol, absorption on the macro-reticular ion exchange resin and desorption of the liquid extract, separation of the ganglioside mixture, separation of monosialic-tetrahexosol gangliosides of the raw product, followed by its purification, drying and packaging under certain conditions are carried out. The neuroprotective agent in the form of a solution for injections. EFFECT: method allows to obtain a substance of high purity, suitable for the preparation of injection products. 2 cl, 3 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 632 710 C2 (51) МПК A61K 35/12 (2015.01) A61K 31/7032 (2006.01) A61P 25/00 (2006.01) C07H 15/06 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (21)(22) Заявка: 2016112141, 31.03.2016 (24) Дата начала отсчета срока действия патента: 31.03.2016 (73) Патентообладатель(и): Лонг Шенг Фарма Лимитед (HK) Дата регистрации: (56) Список документов, цитированных в отчете о поиске: Свиридова А.П., Копоть О.В. Приоритет(ы): (22) Дата подачи заявки: 31.03.2016 (43) Дата публикации заявки: 05.10.2017 Бюл. № 28 (54) Способ получения натрий моносиалового ганглиозида и нейропротекторное средство на его основе (57) Реферат: Изобретение относится к фармацевтической ганглиозидной смеси, отделение промышленности, а именно к способу выделения моносиалотетрагексозиловых ганглиозидов моносиалотетрагексозилганглиозида натрия сырьевого продукта с его последующей очисткой, (GM1). Способ выделения GM1 заключается в сушкой и упаковкой при определенных условиях. том, что готовят экстракт свиного мозга с Нейропротекторное средство в форме раствора использованием смеси трихлорметана, для инъекций. Вышеописанный способ позволяет метилового спирта, проводят абсорбцию на получить субстанцию высокой чистоты, макроретикулярной ионообменной смоле и пригодную для получения инъекционных десорбцию жидкого экстракта, разделение ...

Glycosyl-inositol-phospho-ceramides (GIPC), process for their preparation and their use

Die vorliegende Erfindung stellt ein Verfahren zur Isolierung von Glycosyl-Inosit-Phopho-Ceramiden und ihre Verwendung als Immunmodulatoren zur Verfügung. Das erfindungsgemäße Verfahren weist die folgenden grundlegenden Schritte auf: DOLLAR A A) Herstellen eines Aufschlusses von Basidiomyceten; DOLLAR A B) Entfernen des Wassers aus dem Aufschluss; DOLLAR A C) Herstellen einer Suspension des getrockneten Aufschlusses in einem organischen Lösungsmittel; DOLLAR A D) Trennen der Suspension in einen Festanteil und einen Überstand; und DOLLAR A E) Isolieren der Glycosyl-Inosit-Phospho-Ceramide aus dem Überstand mittels einer Säulenchromatographie. DOLLAR A Die Glycosyl-Inosit-Phopho-Ceramide weisen die Grundstruktur X-Manß-2Ins1-Phospho-Ceramid, wobei X ein glycosydischer Substituent ist. The present invention provides a method for isolating glycosyl-inositol-phospho-ceramides and their use as immunomodulators. The method according to the invention has the following basic steps: DOLLAR A A) Preparation of a digest of Basidiomycetes; DOLLAR A B) removing the water from the digestion; DOLLAR A C) Preparation of a suspension of the dried digestion in an organic solvent; DOLLAR A D) separating the suspension into a solid and a supernatant; and DOLLAR A E) Isolate the glycosyl-inositol-phospho-ceramides from the supernatant by means of column chromatography. DOLLAR A The glycosyl-inositol-phospho-ceramides have the basic structure X-Manß-2Ins1-phospho-ceramide, where X is a glycosydic substituent.

A kind of preparation method of Ginsenoside compound K-chitosan micelle nanoparticle

本发明提供了一种人参皂苷CK‑壳聚糖胶束纳米粒的制备方法。本发明制备方法包括如下步骤：(a)脱氧胆酸与O‑羧甲基壳聚糖反应，得到脱氧胆酸‑O‑羧甲基壳聚糖聚合物载体；(b)将脱氧胆酸‑O‑羧甲基壳聚糖聚合物载体在溶液中分散，搅拌；超声处理后，过滤、干燥，得到壳聚糖自组装胶束纳米粒；(c)将人参皂苷CK溶液加入壳聚糖自组装胶束纳米粒的分散液中，并搅拌；超声处理后，透析、过滤，然后干燥，得到人参皂苷CK壳聚糖胶束纳米粒。本发明中，通过采用壳聚糖胶束纳米粒进行人参皂苷CK负载的方法，可以提高抗癌药物人参皂苷CK的水溶性，增强其治疗的有效性、稳定性、靶向性及生物利用率。

Pharmaceutical composition for preventing or treating inflammatory disease comprising pterostilbene 4’-glucoside

본 발명은 테로스틸벤 4'-글루코시드(pterostilbene 4'-glucoside)를 유효성분으로 함유하는 염증성 질환 예방 또는 치료용 약학조성물에 관한 것으로, 상기 테로스틸벤 4'-글루코시드는 헴 옥시게나아제-1(HO-1) 또는 트리스테트라폴린(TTP)의 발현 증가를 유도하여 LPS 자극에 의해 유도된 염증성 사이토카인의 감소에 탁월한 효과를 나타내는 것이 확인됨에 따라, 테로스틸벤-4'-글루코시드를 유효성분으로 포함하는 조성물은 효과적인 염증성 질환 치료제로 사용될 수 있다.

Nanoformulation and methods of use of thyroid receptor beta1 agonists for liver targeting

A composition and an associated method for hepatic targeted delivery of thyroid receptor beta1 (TRβ1) agonist to a liver of a subject. The composition includes hydrophobic nanoparticles, a liver targeting moiety exterior to each nanoparticle and covalently bonded to each nanoparticle, and at least one TRβ1 agonist encapsulated within each nanoparticle. The nanoparticles include chitosan hybrid nanoparticles, amine-modified PLGA nanoparticles, solid lipid nanoparticles, and combinations thereof. The liver targeting moiety includes Glycyrrhetinic acid (GA), Lactobionic acid (LA), or combinations thereof.

Ghrelin secretion promoter

本发明涉及新的生长素释放肽分泌促进剂。更具体地，本发明涉及包含蛋白水解产物和发酵乳蛋白作为蛋白质、中链脂肪酸作为脂质、和糖质的生长素释放肽分泌促进剂。

Process for preparing solid formulation of deer antlers fermenting material having high ganglioside contents

본 발명은 높은 강글리오사이드 함량을 지니는 녹용 발효물 고형 제제의 제조 방법에 관한 것이다. 더욱 상세하게는 분쇄 살균시킨 녹용을 온수에 넣고 유산균(Lactobacillus plantarum) 배양액을 넣어 1차 발효시킨 후 1차 발효생성물을 열수로 추출하고 추출된 1차 발효생성물에 홍국균(Monascus purpureus) 배양액을 넣어 2차 발효시킨 후 2차 발효생성물을 열수로 추출하고 또다시 추출된 2차 발효생성물을 황국균(Aspergillus orizae) 배양액을 넣어 3차 발효시킨 후 3차 발효생성물을 열수로 추출한 후 농축 감압 건조시킨 1.0 중량% 이상의 강글리오사이드 함량을 지니는 녹용 발효 추출물의 제조 방법 및 녹용 발효 추출물에 유당 등의 부형제를 첨가시킨 녹용 발효물 고형 제제의 제조 방법에 관한 것이다.

GLYCOSIDES OF N-ACETYL-6-O- (2,2-BIS (HYDROXIMETHYL) -3-HYDROXYPROPIL) -D-GLUCOSAMINE, PROCEDURE OF OBTAINING AND USE IN THE TREATMENT OF BRAIN TUMORS.

Glicósidos de N-acetil-6-O-[2,2-bis(hidroximetil)-3- hidroxipropil]-D-glucosamina, procedimiento de obtención y uso en el tratamiento de tumores cerebrales. En ésta patente se describe un procedimiento de obtención de glicósidos derivados del monasacárido N-acetil-D-glucosamina y la investigación sobre su actividad inhibitoria y citotóxica de glioblastomas. Se han preparado glicósidos de fórmula general 1 a partir del monosacáridos N-acetil-D-glucosamina, donde el aglicón R{sup,1} es un resto de naturaleza hidrofóbico, preferentemente una cadena hidrocarbona de 8-16 carbonos, lineal o ramificada. Uso de los glicósidos de N-acetil-6-O- [2,2-bis(hidroximetil)-3-hidroxipropil]-D-glucosamina para inhibición de la proliferación de gliomas humanos en cultivo. Glycosides of N-acetyl-6-O- [2,2-bis (hydroxymethyl) -3-hydroxypropyl] -D-glucosamine, procedure for obtaining and using in the treatment of brain tumors. This patent describes a procedure for obtaining glycosides derived from the N-acetyl-D-glucosamine monasaccharide and research on its inhibitory and cytotoxic activity of glioblastomas. Glycosides of general formula 1 have been prepared from the N-acetyl-D-glucosamine monosaccharides, where the aglycone R {sup, 1} is a hydrophobic nature residue, preferably an 8-16 carbon hydrocarbon chain, linear or branched. Use of N-acetyl-6-O- [2,2-bis (hydroxymethyl) -3-hydroxypropyl] -D-glucosamine glycosides for inhibition of the proliferation of human gliomas in culture.

It is a kind of to treat pharmaceutical composition of central nervous system disease and its production and use

本发明公开了一种治疗中枢神经系统疾病的药物组合物，该药物组合物是由以下重量比组成：红景天苷5～60重量份，红芪多糖1～30重量份。本发明还提供了该药物组合物的制备方法。本发明还提供了该药物组合物的制备方法和具体用途。本发明药物组合物经药效实验证明可通过降低脑组织中的氧化产物和提高脑内抗氧化酶活性明显改善D‑半乳糖致痴呆小鼠模型的学习记忆能力，并能明显改善血管性痴呆大鼠的认知功能。同时，本发明药物配伍后具有不同程度的降血脂作用。

Pharmaceutical composition for treating diabetes

本发明涉及一种治疗糖尿病的药物组合物，本发明药物是以爵床脂素 A、葫芦素E、鞭打绣球苷B、海州常山苦素A为原料药，配比而成，可按常规制剂工艺制成各种剂型，本发明克服了现有技术的缺陷，提供了一种治疗糖尿病的药物组合物。

Method for preparing wheat germ agglutinin-conjugated praecoxin A

본 발명은 암세포 성장 억제와 전이 억제 활성을 갖는 단백질과 화합물의 결합체에 관한 것으로서, 보다 상세하게는 흑색종 세포를 선택적으로 인식하는 기능을 갖는 렉틴과 암세포를 파괴하는 기능을 갖는 엘라지탄닌을 결합시켜 흑색종에 의한 전이를 억제하는 치료제로 사용될 수 있는 렉틴과 엘라지탄닌의 결합체에 관한 것이다. The present invention relates to a combination of a protein and a compound having cancer cell growth inhibition and metastasis inhibiting activity, and more particularly, a lectin having a function of selectively recognizing melanoma cells and an ellagitannin having a function of destroying cancer cells. The present invention relates to a combination of lectin and ellagitannin, which can be used as a therapeutic agent to inhibit metastasis caused by melanoma. 본 발명에 따른 렉틴과 엘라지탄닌 결합체는 흑색종을 특이적으로 인식하여 흑색종 세포의 성장과 전이를 억제할 수 있기 때문에 흑색종에 대한 항암제로서 효과적으로 사용될 수 있다. The lectin and ellagitannin conjugates according to the present invention can be effectively used as anticancer agents for melanoma because they can specifically recognize melanoma and inhibit the growth and metastasis of melanoma cells. 흑색종, 렉틴, 엘라지탄닌 Melanoma, Lectin, Ellagitannin

Composition for the treatment of constipation

A composition containing a synergistic association of lactitol and Rhamnus frangula extract, potentially also in the presence of inulin, for the treatment of constipation is described.

Compositions of crude algal oil

New labdane diterpene glycoside compound, preparation method therefor and applications

本发明公开了一种新的劳丹烷型二萜苷化合物及其制备方法和用途，涉及医药技术领域，具体是从蔷薇科植物华东覆盆子(Rubus chingii Hu)的干燥果实中，经一定的制备步骤分离到一种新的劳丹烷型二萜苷化合物，称为覆盆子苷A，覆盆子苷A经超导核磁共振波谱，质谱等多种手段检测，确定其分子式为C 32 H 56 O 14 。分子量为664，化学结构式为式(Ⅰ)。本发明公开了覆盆子苷A的理化性质，光学活性，并采用MTT法进行了体外活性筛选，结果表明对人胃癌细胞和人肝癌细胞有明显的抑制作用，可作为研制新型的抗肿瘤药物的先导化合物，也可作为研制治疗各种临床常见多发癌症的药物。

Application of sarmentosin in preparation of drugs for preventing or treating acute lung injury and pulmonary fibrosis

本发明提供了垂盆草苷的药物新用途，具体涉及垂盆草苷在制备预防或治疗急性肺损伤和肺纤维化的药物中的应用，其使用剂量范围是50mg～1000mg；优选50～500mg。

Ghrelin secretion promoter

Sulfatides as anti-inflammatory compounds

Using in vitro adhesion of recombinant rat L-selectin-Ig or rat neutrophils, it has been demonstrated that these materials bind to sulfatide that has been present in solid phase on a plastic surface. The binding activity appears to have structural requirements, with the sulfate group being critically present in position 3 on the pyranose ring of galactose. When used in vivo, it has been demonstrated that sulfated glycolipids such as brain sulfatide and ganglioside, have significantly protective effects in two models of lung inflammation, the first systemic activation of complement and the second occurring after intrapulmonary deposition of immune complexes. Both inflammatory reactions are complement, neutrophil and selectin-dependent. The protective effects of these compounds are linked to their ability to prevent the recruitment of neutrophils into lung tissue. On the basis of these findings, it is demonstrated by sulfatides and related compounds have significant in vivo anti-inflammatory activities. These compounds thus represent a new class of anti-inflammatory agents.

A kind of application of sugar alcohol composite in the drug of preparation treatment xerophthalmia

本发明公开了一种治疗干眼症的糖醇组合物，以低聚麦芽糖醇粉、赤藓糖醇粉和山梨糖醇粉为原料组合制成，与常用药物制剂辅料制成固体制剂，使用时熏蒸或雾化眼部，该组合物对干眼症具有确定治疗作用。

Use of sphingosine-1-phosphate to suppress programmed cell death

Admisistration of sphingosine-1-phosphate to retard apoptosis in degenerative diseases as neurodegenerative disease, ischemic stroke and aging is disclosed wherein slowing of the process of programmed cell death is useful as a means to slow the degenerative process in patients suffering from these diseases.

Abx196 for use in the treatment of bladder cancer

Use of gangliosides and other substances for modulating sphingolipid-cholesterol microdomains

The invention relates to the use of gangliosides and other substances for producing an agent for modulating sphingolipid-cholesterol microdomains.

Patent RU2020109889A3

Neuroprotective agent from pig brain based on sodium monosial ganglioside

FIELD: pharmacology. SUBSTANCE: neuroprotective agent is a substance based on sodium monosialotetrahexosylganglioside obtained from the pig brain by extraction, precipitation of a gangliosides-containing mixture with a sodium hydroxide solution and its adsorption on a macroreticular ion exchange resin, followed by chromatographic separation on an ion-exchange column, selection of a fraction with sodium monosialotetrahexosylganglioside, determined by thin layer chromatography, dissolution in a mixture of trichloromethane, methyl alcohol and purified water, followed by purification using an ion exchange resin column, activated carbon, cation exchange resin column, filtration and drying, and having the following characteristics: sodium monosialotetrahexosylganglioside content of at least 96%, with a content of 19.0%-21.0% sialic acid residues based on dry matter, pH of the aqueous solution at a concentration of 20 mg per 1 ml - 5.0~6.5, the area of the impurity peak with a molecular weight of more than 5000 daltons is not more than 1.00% of the peak area of sodium monosialotetrahexosylganglioside, moisture content is not more than 5%. EFFECT: improved compound properties. 2 ex

Rhodioside and the like takes off cytoskeleton dynamic in pancreas and the purposes planted in pancreas islet again is perfused

本发明公开了一种红景天苷及其类似物在胰腺脱细胞支架动态灌注再种植胰岛中的用途，是红景天苷及其类似物在制备胰腺脱细胞支架三维动态灌注再种植胰岛中拮抗胰岛机械损伤和中心乏氧、促进胰岛功能的制剂中的应用。本发明效果确切。

Use of ginsenoside m1 for preventing or treating gout

The present invention discloses a new use of ginsenoside M1 for treating or preventing gout.

Compounds for stimulating nerve growth

Compounds which can stimulate neuronal growth by inhibiting the neuronal inhibitory activity of myelin-associated glycoprotein (MAG), and a method of using the compounds for stimulating neuronal growth are provided. The invention further provides a method of identifying compounds which inhibit myelin-associated glycoprotein inhibition of axonal outgrowth of injured nerve cells. The method involves contacting the compound with myelin-associated glycoprotein under conditions which allow myelin-associated glycoprotein and the compound to bind and detecting the binding.

Application of thio-isorhamnetin diacylglycerol

本发明公开了一种具有如式Ⅰ所示结构的硫代异鼠李糖基二酰甘油酯用于制备止血药物的应用。 I式I中的R 1 或R 2 代表酰基片段，所述酰基片段为含1‑30个碳原子的直链或支链脂肪酸；且酰基片段中含0‑15个顺式或反式双键。本发明的止血药物可作用于凝血共同途径从而发挥止血作用。本发明止血药物具有良好的体外、体内止血效果。止血作用机制明确，毒副作用小。本发明所用原料来源广泛，提取工艺简单，价格便宜。

Medicine composition for treating diabetes

本发明涉及一种治疗糖尿病的药物组合物，本发明药物是以萝卜硫苷、当药苦苷、鞭打绣球苷B、海州常山苦素A为原料药，配比而成，可按常规制剂工艺制成各种剂型，本发明克服了现有技术的缺陷，提供了一种治疗糖尿病的药物组合物。

Abx196 for use in the treatment of bladder cancer

Allergy-protective formula food with gangliosides

The invention concerns the use of gangliosides containing N-acetyl neuraminic acid for allergy protection in humans and animals, especially premature and suckling infants and small children. According to the invention, an allergy-protective formula food containing these gangliosides is also produced.